gemcitabine has been researched along with Benign Neoplasms in 514 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 49 (9.53) | 18.2507 |
| 2000's | 179 (34.82) | 29.6817 |
| 2010's | 242 (47.08) | 24.3611 |
| 2020's | 44 (8.56) | 2.80 |
| Authors | Studies |
|---|---|
| Bergman, AM; Loves, WJ; Peters, GJ; Pinedo, HM; Talianidis, I; van der Wilt, CL; Veerman, G | 1 |
| Bouska, J; Gandhi, VB; Giranda, VL; Gong, J; Guan, R; Jarvis, K; Johnson, EF; Jong, RD; Klinghofer, V; Li, Q; Liu, X; Luo, Y; Magnone, SR; Oleksijew, A; Oltersdorf, T; Park, C; Rosenberg, SH; Shi, Y; Shoemaker, A; Zhu, GD | 1 |
| Gately, S; Gonzales, P; Sepulveda, M; Wang, T | 1 |
| Chen, XY; Chen, Y; Feng, P; Guo, YL; Huang, YQ; Liu, MM; Yang, G | 1 |
| Foxley, MA; Gurrapu, S; Jonnalagadda, SK; Lueth, EA; Mereddy, VR; Nelson, GL; Ronayne, CT; Solano, LN | 1 |
| Džubák, P; Gurská, S; Hajdúch, M; Hejtmánková, K; Hocek, M; Lišková, B; Oždian, T; Pohl, R; Smoleń, S; Tichý, M; Tloušt'ová, E | 1 |
| Maiti, S; Paira, P | 1 |
| Cheng, H; Deng, M; Ding, Z; Dou, G; Hou, Y; Li, F; Li, W; Ma, M; Zhao, J | 1 |
| de Lima Ferreira, LP; de Melo Rêgo, MJB; de Moraes Gomes, PAT; de Siqueira, LRP; Leite, ACL | 1 |
| Clemons, WM; Gillman, CD; Glazer, ES; Hevener, KE; Hussain, SM; Kansal, RG; Kurosu, M; Miranda-Carboni, GA; Mitachi, K; Yun, HG | 1 |
| Bononi, G; Caligiuri, I; Canzonieri, V; Chicca, A; Ferrisi, R; Gertsch, J; Giovannetti, E; Glasmacher, S; Gori, E; Granchi, C; Macchia, M; Mantini, G; Minutolo, F; Palazzolo, S; Perin, T; Poli, G; Rizzolio, F; Sodi, A; Tuccinardi, T | 1 |
| Chen, Q; Chen, W; Qin, L; Sun, J; Wang, G; Wang, Y | 1 |
| Miao, Z; Wang, C; Wang, Y; Wu, Y; Ye, S; Zhang, H; Zhang, Y; Zhu, Y | 1 |
| Chen, G; Li, H; Liu, M; Lu, W; Svirskis, D; Wen, J; Ying, M | 1 |
| Duan, X; Fang, Y; Fang, Z; Lin, D; Liu, H; Luo, M; Miao, C; Wu, J; Zhang, X; Zhong, W | 1 |
| Bajor, D; Bauer, T; Davar, D; Holland, A; Luke, JJ; Merghoub, T; Naik, GS; Newman, W; Piper, D; Qi, J; Rixe, O; Sato, T; Sifferlen, L; Sirard, CA; Wang, H; Wolchok, JD; Wong, P; Zappasodi, R | 1 |
| Costantini, A; Fabre, L; Giroux-Leprieur, E; Magdelaine, P | 1 |
| Hernandez-Guerrero, T; Moreno, V | 1 |
| Chen, Y; Feng, W; Feng, Y; Li, H; Liu, H; You, H; Zheng, Q | 1 |
| Chen, JA; Gandara, DR; Huynh, JC; Kelly, KL; Kim, EJ; Li, T; Mack, PC; Mahaffey, N; Martinez, A; Matsukuma, K; Riess, JW; Semrad, TJ; Tam, K; Wu, CY; Yu, AM | 1 |
| Chen, L; Fu, X; Gao, Q; Han, L; Huang, H; Li, H; Li, T; Liu, Y; Peng, L; Qin, P; Till, BG; Wang, W; Wang, Z; Yan, X; Yang, Y; Ye, Z; Zhang, B; Zhang, X; Zhao, L | 1 |
| Anderson, B; Azaro, A; Benhadji, KA; Cassier, PA; Massard, C; Oakley, G; Pant, S; Yu, D; Yuen, E | 1 |
| Ajona, D; Alignani, D; Aparicio, B; Barace, S; Conde, E; Egea, J; Guruceaga, E; Hervás-Stubbs, S; Lasarte, JJ; Llopiz, D; Navarro, F; Repáraz, D; Ruiz, M; Sarobe, P; Senent, Y; Silva, L | 1 |
| Anthoney, A; Arkenau, T; Banerji, U; Blagden, S; Carter, L; Garralda, E; Jones, R; Klencke, BJ; Kowalski, MM; Kristeleit, R; Moreno, V; Plummer, R; Roda, D; Roxburgh, P; Sarker, D; Walter, HS | 1 |
| Coppens, E; Couvreur, P; Lirussi, F; Lopez, T; Mura, S; Pyrshev, K; Ramseyer, C; Rivel, T; Yesylevskyy, S | 1 |
| Li, J; Li, Y; Wang, J; Wu, Y; Xu, X; Zhang, A; Zhang, Z | 1 |
| Bigi, F; Cavazza, A; González-Ballesteros, N; Grimaldi, M; Lastra-Valdor, M; Maietta, I; Rey-Méndez, R; Rodríguez-Argüelles, MC; Simón-Vázquez, R | 1 |
| Aklilu, AM; Shirali, AC | 1 |
| Chen, G; Li, Y; Li, Z; Lin, L; Tang, Y; Wang, S; Wang, X; Wei, L; Xie, J; Xiong, S; Yu, K; Yu, Z; Zhang, B | 1 |
| Bian, S; Chen, X; Shi, X; Shu, L; Wan, J; Wang, H; Wang, M; Yao, J; Yao, Q; Zhang, F; Zheng, S | 1 |
| Ali, SW; Fatima, N; Hameed, A; Jabeen, A; Qazi, AS; Safdar, W; Tariq, MR | 1 |
| Du, YR; Gao, H; Ji, ZJ; Jiang, H; Jiang, W; Pang, GZ; Sheng, MY; Walsh, CP; Wang, XQ; Wang, YX; Wu, WL; Wu, YS; Xie, JY; Xu, GL; Zhang, L; Zhao, YH; Zhou, D | 1 |
| Arias, JL; Caro, C; Fernández-Álvarez, F; García-García, G; García-Martín, ML | 1 |
| Babu, T; Brabec, V; Gandin, V; Gibson, D; Kasparkova, J; Kostrhunova, H; Maji, M; Markova, L; Novohradsky, V; Sarkar, A | 1 |
| Abbaspour, A; Dehghani, M; Firuzi, O; Ghorbani, M; Moosavi, F; Omidvari, S; Ramzi, M; Rostamipour, HA; Setayesh, M; Tavakkoli, M | 1 |
| Gao, D; Ji, T; Long, M; Yu, M; Zang, W; Zhang, Z | 1 |
| Chen, X; Luan, Y; Miao, H | 1 |
| Johnson, J; Li, L; Sharick, JT; Skala, MC | 1 |
| Desmaële, D; Gref, R; Lacombe, S; Li, X; Menendez-Miranda, M; Pastor, A; Porcel, E; Qiu, J; Serre, C; Yang, X | 1 |
| Abdel Karim, N; Aljohani, HM; Bahassi, EM; Eldessouki, I; Gaber, O; Morris, J | 1 |
| Ido, S; Kawazoe, H; Matsuo, M; Mori, N; Nakai, M; Nakamura, T; Sumikawa, S; Takeuchi, A; Tsuneoka, K; Uozumi, R; Yakushijin, Y; Yamauchi, M | 1 |
| Barcinska, E; Inkielewicz-Stepniak, I; Sobczak, K; Steckiewicz, KP; Tomczyk, E; Wojcik, M | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Clayton, EA; McDonald, JF; Pujol, TA; Qiu, P | 1 |
| Beijnen, JH; Derissen, EJB | 1 |
| Boras, B; Chen, W; D'Argenio, DZ; Hu, W; Spilker, ME; Sung, T | 1 |
| Almuqbil, RM; da Rocha, SRP; Fines, CB; Heyder, RS; Sunbul, FS | 1 |
| Becerra, CHR; Boyd, TE; Casero, RA; Conkling, PR; Fitzgerald, M; Garbo, LE; Jotte, RM; Marton, LJ; Murray Stewart, T; Richards, DA; Smith, DA; Stephenson, JJ; Vogelzang, NJ; Von Hoff, D; Wu, HH | 1 |
| Hawryłkiewicz, A; Ptaszyńska, N | 1 |
| Brooks, T; Massey, AJ; Wayne, J | 1 |
| Duan, Z; Gong, Q; Gu, Z; Guo, C; Li, N; Luo, K; Wang, L; Zhang, H | 1 |
| Carnevalli, LS; Dunlop, CR; Fernández, SBQ; Jodrell, DI; Johnson, TI; Kottmann, D; Lau, A; Minteer, CJ; Richards, FM; Wallez, Y | 1 |
| Correia, C; Ferreira, A; Lapa, R; Santos, J; Urtti, A; Vale, N; Yliperttula, M | 1 |
| Adjei, A; Attwood, K; Bshara, W; Evans, R; Fountzilas, C; Ghasemi, M; Goey, A; Groman, A; Iyer, R; Ma, WW; Opyrchal, M; Wilton, J | 1 |
| Chourasia, MK; Dyawanapelly, S; Kumar, A | 1 |
| Gujral, TS; Kirschner, MW | 1 |
| Aspeslagh, S; Douchet, G | 1 |
| Lee, SH; Nilofar Danishmalik, S; Sin, JI | 1 |
| Andreiuk, B; Bort, G; Cayre, F; Couvreur, P; Dalbin, L; Desmaële, D; Klymchenko, AS; Lepetre-Mouelhi, S; Mougin, J; Mura, S; Paul, JL; Pieters, G; Ramseyer, C; Sobot, D; Yesylevskyy, SO | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Ghazaly, E; Peters, GJ; Rizzuto, I | 1 |
| Angevin, E; Cassier, PA; Drubay, D; Gazzah, A; Gonçalves, A; Gravis, G; Hollebecque, A; Italiano, A; Paci, A; Parlavecchio, C; Poinsignon, V; Soria, JC; Terret, C; Toulmonde, M; Varga, A | 1 |
| Almokadem, S; Appleman, L; Belani, CP; Beumer, JH; Carneiro, BA; Chen, A; Chu, E; Ding, F; Hershberger, PA; Holleran, J; Jiang, Y; Ken Czambel, R; Kiesel, BF; Kontopodis, E; Lin, Y; Petro, D; Puhalla, S; Rachid, M; Schmitz, JC; Stoller, R | 1 |
| Bauer, S; Burgess, P; Doerfel, S; Forget, F; Kalambakas, S; Karaszewska, B; Khan, D; Mostafa Kamel, Y; Safran, H; Winer, ES | 1 |
| Fan, L; Song, C; Tan, J; Wu, H; Yang, Q; Zhao, S | 1 |
| Cavaliere, A; Probst, KC; Slusarczyk, M; Westwell, AD | 1 |
| Fujii, H; Hamamichi, S; Hori, Y; Ito, K; Matsui, J; Ozawa, Y; Umeda, IO | 1 |
| Alcindor, T; Chan, E; Chao, R; Chiorean, EG; Gabrail, NY; Hurwitz, H; O'Dwyer, PJ; Potvin, D | 1 |
| Eshima, K; Fukushima, M; Iizuka, K; Jin, C; Zhang, C | 1 |
| Chen, Z; Cui, Z; Shi, Y; Zheng, Y | 1 |
| Leblanc, RM; Pardo, J; Peng, Z | 1 |
| Chen, L; Chu, Z; Huang, C; Huang, Y; Jia, N; Wang, Z | 1 |
| Chen, H; He, Z; Li, L; Li, N; Sun, J; Sun, Z; Tan, X; Wang, K; Zhang, H | 1 |
| Beatson, R; Burchell, JM; Graham, R; Taylor-Papadimitriou, J | 1 |
| Blackwood, EM; Cousin, S; DuPree, K; Epler, J; Hamilton, E; Hollebecque, A; Infante, JR; Italiano, A; Lauchle, JO; LoRusso, PM; Lu, X; Mahrus, S; Moein, A; Moore, KN; Murray, ER; Peale, FV; Postel-Vinay, S; Schutzman, JL; Shapiro, GI; Soria, JC; Tagen, M; Tolaney, S; Toulmonde, M | 1 |
| Cho, NH; Hyun, YM; Jun, CD; Lee, SH; Lee, WJ; Park, SA; Seo, SU; Zou, Y | 1 |
| Huang, Y; Liu, S; Lu, W; Xu, Y; Yu, J; Zhang, X | 1 |
| Fetterly, G; Fountzilas, C; Iyer, R; Javle, M; Johnson, C; Ma, Y; Tan, W | 1 |
| Burtey, S; Coppo, P; Daviet, F; Duffaud, F; Frémeaux-Bacchi, V; Grandvuillemin, A; Grange, S; Jourde-Chiche, N; Mancini, J; Micallef, J; Moussi-Francès, J; Poullin, P; Pourroy, B; Rouby, F; Sabatier, R; Sallée, M | 1 |
| Benigno, BB; Clayton, EA; Huang, C; Matyunina, LV; McDonald, JF; McDonald, LD; Vannberg, F | 1 |
| Adjei, AA; Boland, P; Brady, W; Dy, GK; Fetterly, G; Iyer, R; LeVea, C; Ma, WW; Mantione, K; Pitzonka, L; Schihl, S; Straubinger, RM; Tan, W; Whitworth, A; Wilton, J; Xie, H | 1 |
| Ji, Z; Xu, C; Xu, R; Zhu, J | 1 |
| Kim, NR; Kim, YJ | 1 |
| Ciccolini, J; Giovannetti, E; Honeywell, RJ; Peters, GJ | 1 |
| Balboni, B; Benaim, E; El Hassouni, B; Giovannetti, E; Heaton, C; Honeywell, RJ; Kim, DJ; Lee, YB; Peters, GJ; Peterson, C; Poore, J; Sarkisjan, D | 1 |
| Abuzaid, H; Alonso, MJ; Bradshaw, TD; Cadete, A; Marlow, M; Štaka, I; Surikutchi, BT | 1 |
| Chang, SF; Godec, A; Hawkins, WG; Hirbe, AC; Prudner, BC; Rathore, R; Robinson, AM; Van Tine, BA | 1 |
| Feng, J; Jin, X; Ma, Y; Mou, Q; Su, Y; Yan, D; Zhang, C; Zhu, L; Zhu, X | 1 |
| He, H; Hu, J; Li, G; Ma, B; Su, X; Wang, Y; Yu, T; Zhuang, W | 1 |
| Bhuniya, S; Han, JH; Jeon, HM; Kang, C; Kim, JS; Lee, JH; Maiti, S; Park, N | 1 |
| Jain, NK; Jain, V; Mehra, NK; Singh, R | 1 |
| Chen, I; McDermott, DF; Michaelson, MD; Patyna, S; Ruiz-Garcia, A; Ryan, DP; Schwarzberg, AB; Shapiro, GI; Stephenson, P; Tye, L; Zhu, AX | 1 |
| Bessard, R; Bourgeois, H; Douillard, JY; Gamelin, E; Grudé, F; Metges, JP; Riché, C; Vidal, AM | 1 |
| Alexandre, J; Awada, A; Besse-Hammer, T; Faivre, S; Gianella-Borradori, A; Goldwasser, F; Jego, V; Raymond, E; Rejeb, N; Trandafir, L | 1 |
| Bellew, KM; Bendell, JC; Burris, HA; Cox, DS; Durante, M; Infante, JR; Jones, SF; Le, NT; Papadopoulos, KP; Park, JJ; Patnaik, A; Rasco, D; Smith, L; Tolcher, AW | 1 |
| Bondarev, GN; Filatov, MV; Ibatulin, FM; Kovalëv, RA; Stam, TA | 1 |
| Benhadji, KA; Makiuchi, T; Nokihara, H; Sekiguchi, R; Slapak, CA; Tamura, T; Uenaka, K; Yamada, Y; Yamamoto, N | 1 |
| Bedard, PL; Chen, EX; Chen, Z; Clarke, BA; Cohen, B; Hirte, HW; Hotte, SJ; Ivy, SP; McWhirter, E; Moore, MJ; Oza, AM; Razak, AR; Reedijk, M; Richter, S; Siu, LL; Stathis, A; Tran, B; Wang, L; Zhang, WJ | 1 |
| Capellà, G; Casanovas, O; Ginestà, MM; Gracova, K; Graupera, M; Laquente, B; Serrano, T; Viñals, F; Vives, M | 1 |
| Asthana, S; Chourasia, MK; Gupta, A; Konwar, R | 1 |
| Carazo, A; Delgado, AV; Gómez-Sotomayor, R; Munoz-Gamez, JA; Rudzka, K; Ruiz-Extremera, A; Salmerón, J; Viota, JL | 1 |
| Couvreur, P; Desmaële, D; Harrisson, S; Maksimenko, A; Nicolas, J; Trung Bui, D; Vauthier, C | 1 |
| Lin, F; Qi, WX; Shen, Z; Sun, YJ; Tang, LN; Yao, Y | 1 |
| Han, JH; He, Y; Hong, KS; Jeon, HM; Kang, C; Kim, JS; Lee, H; Lee, JH; Park, N; Yang, Z | 1 |
| Blackwood, E; Cain, G; Choi, J; Epler, J; Evangelista, M; Flagella, M; Gazzard, L; Halladay, J; Jackson, PK; Jakubiak, D; Kowanetz, K; Malek, S; O'Brien, T; Ramiscal, J; Schmidt, S; Williams, K; Wong, K; Xiao, Y; Yee, S; Yen, I | 1 |
| Kakudo, Y; Kameno, K; Kanai, M; Kim, YH; Kitano, T; Matsumoto, S; Mishima, M; Mori, Y; Nagai, H; Nakata, K; Nishimura, T; Sato, H; Takashima, S; Yamaguchi, T; Yanagihara, K; Yasuda, H | 1 |
| Agbo, F; Arita, S; Esaki, T; Fujimoto, C; Hamatake, M; Hirai, F; Kometani, T; Makiyama, A; Nosaki, K; Seto, T; Shi, X; Takeoka, H | 1 |
| Lopes, Gde L | 1 |
| Blackwood, E; Del Nagro, C; Evangelista, M; Jackson, PK; Kowanetz, K; Malek, S; O'Brien, T; Ramiscal, J; Xiao, Y | 1 |
| Gaur, S; Horne, D; Hu, S; Hu, W; Smith, DL; Su, L; Synold, TW; Wu, J; Yen, Y; Yip, ML; Yuan, YC; Zhou, B | 1 |
| Cheng, Y; Dong, W; Hu, Y; Li, R; Sun, J; Tao, H; Wang, J; Wu, B | 1 |
| Carvalheira, JB; Leal, F; Macedo, LT | 1 |
| Barda, D; Barnard, D; Blosser, W; Clawson, D; Cox, K; Diaz, H; Guo, S; King, C; Marshall, M | 1 |
| Balza, E; Borsi, L; Carnemolla, B; Castellani, P; Mortara, L; Orecchia, P | 1 |
| Bui, DT; Couvreur, P; Desmaële, D; Maksimenko, A; Nicolas, J | 1 |
| Cha, H; Cho, WJ; Dung, le TK; Lee, HY; Lee, SJ; Min, YJ; Moon, CH; Park, JW | 1 |
| Lecca, P | 1 |
| Kaniwa, N; Knights, J; Ramanathan, M; Saito, Y; Sato, Y; Ueno, H | 1 |
| Adams, S; Baum, J; Fitzgerald, JB; Harms, BD; Iadevaia, S; Jiao, Y; Johnson, BW; Kohli, N; Lugovskoy, AA; Nielsen, UB; Olivier, KJ; Razlog, M; Rennard, R; Rimkunas, V; Schoeberl, B; Tang, J; Xu, L | 1 |
| Brundage, RC; Dudek, AZ; Fisher, J; Greeno, EW; Gurvich, VJ; Khatri, A; Kirstein, MN; Kratzke, RA; Lamba, JK; Lis, LG; Skubitz, KM; Williams, BW | 1 |
| Apetoh, L; Ghiringhelli, F | 1 |
| Alexandre, J; Coronado, C; Dios, JL; Faivre, S; Fernández-García, EM; Goldwasser, F; Kahatt, CM; Miguel-Lillo, B; Paramio, PG; Raymond, E | 1 |
| Baumgartner, S; Kunz, M; Urech, K; Weissenstein, U | 1 |
| Alemany, R; Cascalló, M; Laborda, E; Moreno, R; Puig-Saus, C; Rodríguez-García, A | 1 |
| Agbo, F; Azad, N; Barker, P; Carducci, M; Carter, J; Cosgrove, D; Knight, R; Lorusso, P; Malburg, L; Oakes, P; Quinn, MF; Sausville, E; Senderowicz, A; Zabludoff, S | 1 |
| Alexander, DC; Johnson, SP; Lythgoe, MF; Panagiotaki, E; Pedley, RB; Rajkumar, V; Siow, B; Walker-Samuel, S | 1 |
| Brown, K; Dixey, M; Linclau, B; Weymouth-Wilson, A | 1 |
| Haeusler, GM; Lingaratnam, SM; Rischin, D; Seymour, JF; Slavin, MA; Teh, BW; Thursky, KA; Worth, LJ | 1 |
| Abbadessa, G; Bendell, J; Camacho, LH; Chen, Y; Infante, JR; Jones, S; Kazakin, J; Kurkjian, CD; Moore, KM; Pant, S; Saleh, M; Schwartz, B; Wang, Y | 1 |
| Alberts, SR; Borad, MJ; Costello, BA; Erlichman, C; Kim, GP; Northfelt, DW; Qi, Y | 1 |
| Aguirre, E; Benhadji, KA; Callies, S; Garcia, M; Gil-Martín, M; Llombart, A; Morales, S; Oaknin, A; Salazar, R; Wickremsinhe, ER | 1 |
| Ambre, AH; Gange, KN; Haldar, MK; Katti, KS; Layek, B; Mallik, S; Meghnani, V; Nahire, R; Paul, S; Sarkar, K; Singh, J | 1 |
| Bruchard, M; Ghiringhelli, F | 1 |
| Busman, T; Cleary, JM; Franklin, C; Graham, A; Holen, K; Hurwitz, HI; Lima, CM; Mabry, M; Montero, AJ; Shapiro, GI; Uronis, H; Yang, J | 1 |
| Ajamie, RT; Cai, S; Chan, EM; Cronier, D; de Dios, A; Del Prado, M; Flack, RS; Gelbert, LM; Iversen, P; Kreklau, E; Lallena, MJ; Lin, X; Neubauer, BL; Sanchez-Martinez, C; Torres, R; Wishart, GN; Young, J | 1 |
| Brana, I; Calles, A; Calvo, E; de Boer, CJ; LoRusso, PM; Puchalski, TA; Seetharam, S; Tabernero, J; Yee, LK; Zhong, B | 1 |
| Buoro, RM; Diculescu, VC; Lemos, L; Lopes, IC; Oliveira-Brett, AM; Serrano, SH | 1 |
| Colom, H; García del Muro, X; Gil-Martín, M; Gonzalo, N; Martin-Liberal, J; Muñoz, C; Rigo, R; Sáinz-Jaspeado, M; Tirado, OM | 1 |
| Galsky, MD; Gimpel-Tetra, K; Godbold, J; Holcombe, RF; Lee, KM; Lowe, N; Misiukiewicz, K; Oh, WK; Posner, M; Soto, R; Tsao, CK | 1 |
| Groth, P; Jones, RM; Kotsantis, P; Petermann, E; Stewart, GS | 1 |
| Hirano, T; Katano, M; Kiyota, A; Koya, N; Morisaki, T; Onishi, H; Tanaka, H; Umebayashi, M | 1 |
| Forget, F; Hartner, L; Johnson, BM; Karaszewska, B; Kumar, K; Mayer, B; Messam, CA; Mostafa Kamel, Y; Ramlau, R; Richards, DA; Safran, H; Winer, ES | 1 |
| Becerra, CR; Braiteh, F; Chen, J; Chow, KH; Conkling, PR; Garbo, L; Ilaria, R; Jotte, RM; Richards, DA; Robert-Vizcarrondo, F; Smith, DA; Stephenson, J; Tai, DF; Turner, PK; Von Hoff, DD | 1 |
| Ahn, CH; Fine, T; Kashi, R; Kaye, J; Kim, DJ; Lee, YB; Ohne, O; Peters, GJ; Smid, K; Yang, MY | 1 |
| Cass, CE; Damaraju, VL; Kuzma, M; Mowles, D; Sawyer, MB | 1 |
| Bendell, J; Burke, W; Burris, H; Chau, I; Fielding, A; Hochster, H; Middleton, MR; O'Reilly, EM | 1 |
| Chen, W; Ding, X; Fan, H; Zhu, B | 1 |
| Dobbelstein, M; Kunze, M; Loock, AC; Schmidt, F | 1 |
| Ashworth, MT; Daud, AI; Freshwater, T; Goldman, JW; Grabowsky, JA; Isaacs, R; Kang, SP; Loechner, S; Mendelson, D; Munster, PN; Parry, D; Rosen, LS; Shanahan, F; Shumway, S; Sorge, C; Springett, G; Strosberg, J; Venook, AP | 1 |
| Cutrera, J; Gumpel, E; Jones, P; Kicenuik, K; King, G; Li, S; Xia, X | 1 |
| Anders, CK; Bickford, LR; Brooks, CR; Byrne, JD; Darr, D; Deal, A; DeSimone, JM; Hyder, N; Jajja, MR; Keeler, AW; Lee, W; Little, RE; Luft, JC; Moffitt, RA; Napier, ME; Nelson, M; O'Neill, AT; Stack, C; Stack, R; Tepper, JE; Wagner, K; Wang, AZ; Yeh, JJ; Zamboni, WC | 1 |
| Babacan, NA; Deveci, K; Kacan, T; Sancakdar, E; Seker, A; Seker, MM; Turesin, AK; Yilmaz, A | 1 |
| Cong, C; Dou, Y; Duan, L; Gao, A; Lai, Q; Sun, Y; Zheng, Y | 1 |
| Eastman, A; Sakurikar, N | 1 |
| Abali, H; Köse, F; Mertsoylu, H; Muallaoğlu, S; Ozyilkan, O; Sezer, A; Sümbül, AT | 1 |
| Terui, Y | 1 |
| Anthony, S; Babiker, HM; Borad, MJ; Buchbinder, A; Grem, J; Keilani, T; Mita, M | 1 |
| Bae, SJ; Kim, JK; Kim, SY; Kwon, K; Lee, YS; Noh, YH; Ryu, SW | 1 |
| Izzedine, H; Perazella, MA | 1 |
| Dai, X; Jiang, Y; Tan, C | 1 |
| Kuter, DJ | 1 |
| Costa, JM; Cotta, RM; da Cunha Neto, SH; de Pinho, ST; Dulikravich, GS; Orlande, HR; Velho, HF | 1 |
| Cohen, RB; Doroumian, S; LoRusso, PM; Morris, JC; Olowokure, OO; Olszanski, AJ; Puzanov, I; Rixe, O; Shen, L; Yin, JY | 1 |
| Di Cresce, C; Ferguson, PJ; Figueredo, R; Koropatnick, J; Maleki Vareki, S; Rytelewski, M; Vincent, MD; Way, C | 1 |
| Barthélémy, C; Décaudin, B; Hebbar, M; Lemahieu, N; Michel, P; Odou, P; Pinçon, C; Romano, O; Simon, N; Vasseur, M | 1 |
| Fujisaka, Y; Furuse, J; Kasuga, A; Kitamura, H; Kurata, T; Matsushita, H; Mukaiyama, A; Nagashima, F; Nakagawa, K; Naruge, D; Nishimura, Y; Nishina, S; Okamoto, W; Shimizu, T; Takasu, A | 1 |
| Doi, T; Fuse, N; Hynes, SM; Lin, AB; Matsubara, N; Naito, Y; Nakamura, T; Shitara, K; Uenaka, K; Yoshino, T | 1 |
| Beachy, SH; Fetterly, GJ; Gibbs, JF; Hylander, BL; Pitoniak, R; Prey, JD; Qiu, J; Repasky, EA; Sen, A; Ullas, S | 1 |
| Fan, M; Li, Z; Liang, X; Shi, B; Wang, H; Yang, D | 1 |
| Benhadji, KA; Callies, S; Cohen, RB; Faivre, SJ; Horn, CL; Myrand, SP; Olszanski, AJ; Ouyang, H; Raymond, E; Riess, H; Wang, X; Weigang-Köhler, K; Wickremsinhe, ER | 1 |
| Bourade, V; Chen, E; Doyle, L; Goel, R; Halford, R; Jonker, D; Keller, D; Laurie, SA; Lheureux, S; Oza, AM; Siu, LL; Wang, L | 1 |
| Kmietowicz, Z | 1 |
| Fushimi, K; Hamada, T; Isayama, H; Koike, K; Matsui, H; Nakai, Y; Yasunaga, H | 1 |
| Aftimos, P; Awada, A; Bahleda, R; Bourbouloux, E; Campone, M; Frenel, JS; Gombos, A; Soria, JC; Varga, A | 1 |
| Kohane, DS; Li, L; Li, M; Tong, R | 1 |
| Atallah, JP; Garcia, G | 1 |
| Atyabi, F; Dinarvand, R; Kazemi, B; Razzazan, A | 1 |
| Ciccolini, J; Giovannetti, E; Peters, GJ; Serdjebi, C | 1 |
| AlMalik, AM; Alsaiari, S; Croissant, JG; Deng, L; Khashab, NM; Lu, J; Tamanoi, F; Zhang, D; Zink, JI | 1 |
| Grimes, DR; Harris, A; Kannan, P; Kavanagh, A; McIntyre, A; Partridge, M; Siddiky, A; Wigfield, S | 1 |
| Bastiat, G; Benoit, JP; Bronte, V; Lollo, G; Mandruzzato, S; Marigo, I; Pinton, L; Pitorre, M; Sasso, MS; Solito, S; Valpione, S | 1 |
| Byrne, KT; Vonderheide, RH | 1 |
| Becerra, C; Bence Lin, A; Braiteh, F; Calvo, E; Galsky, MD; Hurt, K; Hynes, SM; Jameson, G; Lin, J; McKane, S; McWilliams, R; Richards, D; Von Hoff, D; Wickremsinhe, ER | 1 |
| Chisaki, Y; Terada, T; Yano, Y | 1 |
| Gao, D; Guo, Q; Han, B; Li, C; Sun, W; Wang, Q; Wei, X; Xie, X; Zhang, Z; Zhao, P; Zhu, D | 1 |
| Airhart, S; Chamie, K; Cimino, GD; de Vere White, R; Drakaki, A; Haack, K; Henderson, PT; Lin, TY; Malfatti, M; Ognibene, T; Pan, CX; Tepper, CG; Turteltaub, KW; Wang, SS; Yang, H; Zhang, H; Zimmermann, M | 1 |
| Alfaro, V; Aspeslagh, S; Bahleda, R; Extremera, S; Fudio, S; Gyan, E; Hollebecque, A; Salles, G; Soria, JC; Soto-Matos, A; Stein, M | 1 |
| Darko, KO; He, C; Huang, Y; Liu, Z; Peng, M; Su, Q; Tao, T; Yang, X; Yin, T | 1 |
| Hagiwara, M; Hara, M; Hirayasu, K; Kojima, T; Nishiyama, H; Usui, J; Yamagata, K; Yokoyama, C; Yoshino, T | 1 |
| Andre, VA; Beijnen, JH; Callies, S; Jansen, RS; Kloeker-Rhoades, S; Pluim, D; Rosing, H; Schellens, JH; Slapak, CA; Veltkamp, SA; Visseren-Grul, CM | 1 |
| Barbarot, V; Courant-Menanteau, M; Lewden-Bernadac, B; Perrocheau, G; Thomare, P | 1 |
| Goh, BC; Holford, NH; Lee, HS; Lee, SC; Soo, RA; Tham, LS; Wang, L; Yong, WP | 1 |
| Ahn, CW; Bull, JM; Koch, SM; Nagle, VL; Oliver, D; Redwine, M; Rowe, RW; Scott, GL; Strebel, FR | 1 |
| Saijyo, N | 1 |
| Atcher, RW; Nayak, TK; Norenberg, JP; Prossnitz, ER | 1 |
| Benezra, R; Bertolini, F; Colleoni, M; Daenen, LG; Emmenegger, U; Henke, E; Kerbel, RS; Langenberg, MH; Man, S; Mancuso, P; Roodhart, JM; Shaked, Y; Strieter, RM; Tang, T; Voest, EE; Witte, L; Xu, P; Zhu, Z | 1 |
| Bolling, C; Depenbrock, H; Endler, C; Fleeth, J; Graefe, T; Hanauske, AR; Lüdtke, FE; Müller-Hagen, S; Ohnmacht, U; von Scheel, J | 1 |
| Aghajanian, CA; Fury, M; Gerst, S; Goss, TL; Hensley, ML; Konner, J; Larkin, J; Orlando, M; Sabbatini, P; Tai, DF | 1 |
| Alberti, DB; Attia, S; Bailey, HH; Campbell, TC; Cleary, JF; Eickhoff, JC; Holen, KD; Huie, MS; Liu, G; McFarland, TA; Morgan-Meadows, S; Mulkerin, DL; Schelman, WR; Tevaarwerk, AJ; Traynor, AM; Wilding, G | 1 |
| Lipton, L; McCoy, S; McGreivy, J; Price, TJ; Rosenthal, MA; Sun, YN | 1 |
| Furuse, J; Ikeda, M; Ishii, H; Kamatani, N; Kaniwa, N; Kim, SR; Maekawa, K; Morizane, C; Okusaka, T; Ozawa, S; Saijo, N; Saito, Y; Sawada, J; Sugiyama, E; Ueno, H; Yamamoto, N; Yoshida, T | 1 |
| Lawrence, TS; Maybaum, J; Morgan, MA; Parsels, LA | 1 |
| Dasanu, CA | 1 |
| Azuma, H; Inamoto, T; Katsuoka, Y | 1 |
| Hong, WK; Khuri, FR; Kim, ES; Lee, JJ; Lee, JL; Lippman, SM; Liu, S; Shin, DM; William, WN | 1 |
| Hennink, WE; Huber, PE; Lammers, T; Peschke, P; Storm, G; Subr, V; Ulbrich, K | 1 |
| Favaudon, V; Hennequin, C; Quero, L | 1 |
| Georgoulias, V; Kotsakis, A; Marselos, M; Mavroudis, D; Nikolaidou, M; Pappas, P; Saridaki, Z; Souglakos, J; Vardakis, N | 1 |
| Bowen, C; Licea-Perez, H; Wang, S | 1 |
| Dreisbach, L; Kristedja, T; Kurtin, S; Mahadevan, D; Obregon, Y; Von Hoff, DD; Williams, D | 1 |
| de Vries, EG; Eskens, FA; Fox, NL; Gietema, JA; Loos, WJ; Miceli, R; Mom, CH; Oldenhuis, CN; Sleijfer, S; Verweij, J | 1 |
| Alamara, C; Chatzidarellis, E; Georgiadis, E; Giza, L; Makrilia, N; Syrigos, KN | 1 |
| Halldén, G | 1 |
| Booth, CM; Eisenhauer, EA; Ohorodnyk, P | 1 |
| Batzler, A; Fridley, BL; Jenkins, G; Kalari, K; Li, L; Wang, L; Weinshilboum, RM | 1 |
| Candelaria, M; de la Cruz-Hernández, E; Dueñas-González, A; Gutiérrez-Hernández, O; Pérez-Cárdenas, E; Trejo-Becerril, C | 1 |
| Boyer, JC; Brouillet, JP; Ciccolini, J; Evrard, A; Lallemant, B; Lumbroso, S; Mercier, C; Mouzat, K; Polge, A; Raynal, C | 1 |
| Wang, ZY | 1 |
| Blobe, GC; Dugan, E; Fernando, NH; Gockerman, JP; Hurwitz, HI; Meadows, KL; Morse, MA; Petros, WP; Truax, R | 1 |
| Batzel, G; Erlichman, C; Felten, S; Haluska, P; Hubbard, J; Ivy, SP; Qin, R; Stensgard, BA; Ten Eyck, C; Toft, DO | 1 |
| Chow, W; Cristea, M; Doroshow, JH; Frankel, P; Gaur, S; Koczywas, M; Lim, D; Luu, T; Margolin, K; Morgan, RJ; Somlo, G; Yen, Y | 1 |
| Hendzel, MJ; Kaufmann, SH; Patel, A; Poirier, GG; Rouleau, M | 1 |
| Hall, PD; Teusink, AC | 1 |
| Levine, MN | 1 |
| Advani, RH; Fisher, GA; Francisco, B; Galatin, PS; Julian, T; Losa, R; Sierra, MI; Sikic, BI | 1 |
| Danesi, R; Falcone, A; Giovannetti, E; Peters, GJ; Tibaldi, C | 1 |
| Davis, TH; Dragnev, KH; Hardin, SB; Pipas, JM; Rigas, JR | 1 |
| Chen, J; Feng, YH; Gully, C; Lee, MH; Velazquez-Torres, G; Yeung, SC | 1 |
| Pineda de la Losa, F; Prieto García, A | 1 |
| Chan, WC; Dalgleish, AG; Gravett, AM; Haynes, RK; Krishna, S; Liu, WM; Wilson, NL | 1 |
| Bou Reslan, H; Cao, TC; Carano, RA; Cheng, JH; Clermont, AC; Devasthali, V; Forrest, WF; Fuh, G; Hamilton, P; Ho, CC; Johnson, L; Koeppen, H; Lee, CV; Lima, A; Molina, R; Nannini, MA; Plowman, GD; Singh, M; Thompson, JD; Yu, RX | 1 |
| Bustinza-Linares, E; Kurzrock, R; Tsimberidou, AM | 1 |
| Caruso, M; Cottin, S; de Campos-Lima, PO; Ghani, K | 1 |
| Bekaii-Saab, T; Kraut, EH; Serna, DS | 1 |
| Fujii, Y; Iino, Y; Isayama, H; Kamimura, H; Kihara, K | 1 |
| Ahmad, A; Azmi, AS; Banerjee, S; Kong, D; Li, Y; Sarkar, FH; Wang, Z | 1 |
| Furuse, J; Hasegawa, R; Ikeda, M; Ishii, H; Kaniwa, N; Kim, SR; Kondo, S; Morizane, C; Okusaka, T; Saijo, N; Saito, Y; Sawada, J; Sugiyama, E; Tamura, T; Ueno, H; Yamamoto, N; Yoshida, T | 1 |
| Lavi, S; Leitner, O; Lindzen, M; Yarden, Y | 1 |
| Baker, LH; Chenevert, T; Chugh, R; Karantza, V; Mehnert, J; Moss, RA; Poplin, EA; Saraiya, B; Savkina, N; Stein, MN | 1 |
| Van Dyke, T | 1 |
| Aerts, I; Boos, J; Cesare, C; Chisholm, J; Couanet, D; Devos, A; Dias, N; Frappaz, D; Gentet, JC; Geoerger, B; Hain, S; Jaspan, T; Le Deley, MC; Leblond, P; Mc Hugh, K; Riccardi, R; Vassal, G; Zwaan, CM | 1 |
| Cohen, DJ; Hochster, HS; Levinson, B; Love, E; Nicol, SJ; Yaw, M; Yuan, Y | 1 |
| Arkenau, HT; Coffey, M; de Bono, JS; Evans, TR; Gill, G; Harrington, K; Lolkema, MP; Mettinger, K; Morrison, R; Roulstone, V; Roxburgh, P; Twigger, K | 1 |
| Azzi, GR; Choueiri, TK; Je, Y; Nguyen, PL; Schutz, FAB | 1 |
| Meriggi, F; Zaniboni, A | 1 |
| Bommakanti, SV; Dudek, AZ; Gada, PD; Khatri, A; Kirstein, MN | 1 |
| Lawrence, TS; Maybaum, J; Morgan, MA; Normolle, D; Parsels, LA; Zhao, L | 1 |
| Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW | 1 |
| He, A; Ma, S; Sun, Z; Xu, H; Zhao, L; Zheng, X; Zhu, Z | 1 |
| Arias, JL; Couvreur, P; Desmaële, D; Dosio, F; Gillet, B; Gref, R; Othman, M; Reddy, LH; Zouhiri, F | 1 |
| Barile, C; Bolzonella, C; Bononi, A; Crepaldi, G; Gusella, M; Meneghetti, S; Menon, D; Modena, Y; Padrini, R; Pasini, F; Stievano, L; Toso, S | 1 |
| André, N; Ciccolini, J; Dahan, L; Mercier, C | 1 |
| de Souza, PL; Galettis, P; Hoskins, JM; Jelinek, M; Liauw, W; Links, M; Manners, S; Metharom, E | 1 |
| Brooks, D; De Oliveira, E; Demuth, T; Hidalgo, M; Hirai, H; Maitra, A; Mizuarai, S; Ottenhof, N; Rajeshkumar, NV; Shumway, SD; Watters, J | 1 |
| Bendell, JC; Burris, HA; Greco, FA; Infante, JR; Jones, SF; Murphy, PB; Spigel, DR; Thompson, DS; Yardley, DA | 1 |
| Binder, D; Hübner, RH; Schlattmann, P; Temmesfeld-Wollbrück, B | 1 |
| Cai, TY; Dong, XW; He, QJ; Hu, YZ; Jiang, H; Lin, NM; Yang, B; Yang, LQ; Zhang, C; Zhu, H | 1 |
| Curioni, A; Knuth, A; Parvanova, I; Pascolo, S; Rettig, L; Samaras, P; Seidenberg, S | 1 |
| Brendel, E; Kornacker, M; Kummer, G; Schultheis, B; Strumberg, D; Xia, C; Zeth, M | 1 |
| Beijnen, JH; Benhadji, KA; Callies, S; Garcia-Ribas, I; Jansen, RS; Koolen, SL; Kronemeijer, RH; Langenberg, MH; Nol, A; Schellens, JH; Slapak, CA; Voest, EE; Witteveen, PO | 1 |
| Adewoye, AH; Desai, J; Johnson, J; Kotasek, D; McCoy, S; Price, T; Siu, LL; Sun, YN; Tebbutt, N; Welch, S | 1 |
| Batzler, A; Fridley, BL; Jenkins, GD; Ji, Y; Li, F; Li, L; Matimba, A; Wang, L; Weinshilboum, RM | 1 |
| Cui, Z; Digiovanni, J; Kiguchi, K; Kumar, A; Lansakara-P, DS; Rodriguez, BL; Sandoval, MA; Sloat, BR | 1 |
| Adjei, AA; Cutler, DL; Hurwitz, HI; Kaufmann, SH; Meadows, KL; Meyers, ML; Morse, MA; Petros, WP; Rosen, LS; Statkevich, P; Wong, NS; Zhu, Y | 1 |
| Aizawa, K; Fukunaga, E; Hamada, A; Iwata, K; Jingami, S; Saito, H; Sakai, S; Yoshida, M | 1 |
| Celia, C; Cosco, D; Fresta, M; Paolino, D | 1 |
| Adema, AD; Calvo, BD; Diosdado, B; Giovannetti, E; Hodzic, J; Peters, GJ | 1 |
| Apetoh, L; Ghiringhelli, F; Martin, F | 1 |
| Cesta, C; Dantzig, AH; Foster, FS; Francia, G; Hackl, C; Hashimoto, K; Kerbel, RS; Man, S; Shaked, Y; Stewart, J; Sun, J; Uhlik, M; Xu, P; Yin, M | 1 |
| Ishii, M; Kitagawa, N; Maeda, K; Nagaoka, S; Okubo, S; Taketsuna, M; Takeuchi, K; Tatsumi, M | 1 |
| Duvic, M; Falchook, GS; Hong, DS; Kurzrock, R; Lim, J; Naing, A; Wheler, J | 1 |
| Cerqueira, NM; Fernandes, PA; Gesto, DS; Ramos, MJ | 1 |
| Bernard, A; Chauffert, B; Facy, O; Ladoire, S; Magnin, G; Ortega-Deballon, P; Pages, PB; Royer, B | 1 |
| Jafari, M; Kislukhin, G; Long, AD; Murphy, ML | 1 |
| Adjei, AA; Dy, GK; Eckhardt, SG; Jimeno, A; Ma, WW; Maniar, M; Messersmith, WA; Ren, C; Weekes, CD; Whitworth, A; Wilhelm, F | 1 |
| Carter, CA; Figg, WD; Giaccone, G; Gutierrez, M; Ji, J; Kelly, RJ; Kummar, S; Mannargudi, B; Rajan, A; Spencer, S; Szabo, E; Woo, S; Yancey, MA | 1 |
| Diaz, I; Muggia, F; Peters, GJ | 1 |
| Cui, Z; Lansakara-P, DS; Rodriguez, BL | 1 |
| Chan, E; Deng, H; Friberg, G; Gilbert, J; Hwang, YC; Mahalingam, D; McCaffery, I; Michael, SA; Mita, AC; Mita, MM; Mulay, M; Puzanov, I; Rosen, LS; Sarantopoulos, J; Shubhakar, P; Zhu, M | 1 |
| Burris, HA; Greco, FA; Infante, JR; Jones, SF; McCulloch, W; Peacock, NW; Spigel, DR; Thompson, DS | 1 |
| DeSimone, JM; Finniss, M; Gullapalli, A; Luft, JC; Napier, ME; Pandya, A; Parrott, MC | 1 |
| Cai, W; Chen, Y; Liu, T; Xu, J; Zhang, J; Zhou, Y; Zhuang, R | 1 |
| Basu, S; Ghosh, AK | 1 |
| Atsumi, I; Fujita, T; Miki, Y; Nakamichi, H; Nakamura, H; Shiokawa, M; Suzuki, R; Tomita, K; Totsuka, K; Tsuji, D | 1 |
| Li, G; Li, W; Qu, X; Sun, C; Xue, X; Zhao, C | 1 |
| Costanzo, C; Dalla Pozza, E; Dando, I; Donadelli, M; Fiorini, C; Menegazzi, M; Palmieri, M; Sgarbossa, A | 1 |
| Gu, M; Ma, S; Zhang, N; Zhao, L; Zheng, X | 1 |
| Hosokawa, A; Kiba, T; Kozawa, K; Nakashima, T; Ogawa, Y | 1 |
| Chung, WG; Cui, Z; Digiovanni, J; Kiguchi, K; Wonganan, P; Zhu, S | 1 |
| Saif, MW; Strimpakos, AS; Syrigos, KN | 1 |
| Chang, YS; Cho, SH; Kang, SY; Kim, JH; Kim, MH; Kim, MY; Kim, SH; Kim, YJ; Lee, JS; Lee, KW; Lee, SY; Min, KU; Song, WJ; Yang, MS | 1 |
| Dalgleish, AG; Liu, WM | 1 |
| Dudek, AZ; Greeno, EW; Khatri, A; Kirstein, MN; Kratzke, RA; Lamba, JK; Mitra, AK; Skubitz, KM | 1 |
| Bekaii-Saab, T; Deam, D; Grever, MR; Harper, EJ; Hicks, WJ; Ivy, SP; Ling, Y; Liu, X; Liu, Z; Martin, LK; Monk, JP; Mortazavi, A; Otterson, GA; Phelps, MA; Wei, L; Wu, X; Yen, Y; Zhou, BS | 1 |
| Bokar, JA; Brell, JM; Cooney, MM; Dowlati, A; Gibbons, J; Ivy, P; Krishnamurthi, SS; Meropol, NJ; Rath, L; Savvides, P | 1 |
| Harada, M; Harashima, N; Inao, T; Kawauchi, H; Monma, H; Tongu, M; Yamada, T | 1 |
| Gallois-Montbrun, S; Negroni, M; Rossolillo, P; Simon-Loriere, E; Winter, F | 1 |
| Campbell, C; Dwivedi, P; Garg, NK; Tyagi, RK | 1 |
| Ball, HA; Botbyl, J; Gibson, DM; Jeffels, M; Madi, A; Nokay, B; Plummer, R; Richly, H; Rubin, S; Scheulen, ME; Weller, S | 1 |
| Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR | 1 |
| Britti, D; Cosco, D; Federico, C; Morittu, VM; Trapasso, E | 1 |
| Choe, JH; Choe, JM; Falchook, GS; Gallick, GE; George, GC; Hong, DS; Kurzrock, R; Moulder, SL; Naing, A; Piha-Paul, S; Strauss, LC; Wheler, JJ | 1 |
| Apetoh, L; Boireau, W; Bruchard, M; Chalmin, F; Chevriaux, A; Connat, JL; Derangère, V; Ghiringhelli, F; Kanellopoulos, J; Martin, F; Mignot, G; Rébé, C; Ryffel, B; Simon, B; Végran, F | 1 |
| Belaygorod, L; Belt, BA; Brennan, DJ; Carpenter, D; Collins, L; DeNardo, DG; Gallagher, WM; Goedegebuure, P; Hewitt, S; Knolhoff, BL; Linehan, DC; Mitchem, JB; Piwnica-Worms, D; Sanford, DE; Udupi, GM; Wang-Gillam, A; Wegner, C; West, BL; Zhu, Y | 1 |
| Liem, N; Wang, L; Wong, FY; Wong, WC; Xie, C; Yan, FL; Yong, WP | 1 |
| Acharya, AP; Dasari, M; Kim, D; Lee, S; Molinaro, R; Murthy, N; Rhea, J | 1 |
| Fantaccini, G; Kahramanoğullari, O; Lecca, P; Morpurgo, D; Priami, C | 1 |
| Shurin, MR | 1 |
| Dantzig, AH; Durland-Busbice, S; Heinz-Taheny, K; Iversen, PW; Pratt, SE; Shepard, RL | 1 |
| Demolin, G; Focan, C; Graas, MP; Houbiers, G; Stultiens, A | 1 |
| Awada, A; Bergeland, T; Hals, PA; Hendlisz, A; Rasch, W; Schellens, JH; Stuurman, FE; Voest, EE; Witteveen, PO | 1 |
| Hess, KR; Hong, D; Naing, A; Nwosu, U; Tsimberidou, AM; Wheler, J; Wolff, RA; Ye, Y | 1 |
| Senanayake, TH; Vinogradov, SV; Warren, G; Wei, X | 1 |
| Green, MR; Leong, SS; Perkel, JA; Putman, T; Rocha Lima, CM; Safa, AR; Sherman, CA | 1 |
| Benson, A; Mulcahy, M; Musanti, R; Poplin, E; Rubin, E | 1 |
| Fife, K; Ganjoo, KN; Gordon, MS; Loehrer, PJ; Poirier, S; Sandler, AB; Seshadri, R; Warner, RE | 1 |
| de Boeck, G; de Bruijn, E; de Jonge, MJ; Dumez, H; Guetens, G; Highley, M; Louwerens, M; Mantel, M; Pawinsky, A; Planting, AS; Van Oosterom, AT; Verweij, J | 1 |
| Alloisio, M; Antonelli, G; Cavina, R; Dambrosio, M; Latteri, F; Morenghi, E; Ravasi, G; Sala, A; Santoro, A; Soto Parra, H | 1 |
| Cox, K; Faul, MM; Keyes, K; Mann, L; Shih, C; Teicher, BA; Treadway, P | 1 |
| Brierre, JE; Buller, EJ; Cole, JL; Fontenot, MF; Lormand, NA; Rainey, JM; Rinaldi, DA; Stagg, MP | 2 |
| Arquette, MA; Bartlett, NL; Blum, KA; Clark, RS; Fears, CL; Fracasso, PM; Tan, BR | 1 |
| Arquette, MA; Denes, A; Fears, CL; Fracasso, PM; Goodner, SA; Govindan, R; Herzog, TJ; Mutch, DG; Picus, J; Rader, JS; Sun, SL; Tan, BR | 1 |
| Chow, W; Doroshow, JH; Frankel, P; Gandara, D; Lenz, HJ; Leong, L; Longmate, J; Margolin, K; Morgan, R; Newman, EM; Raschko, J; Shibata, S; Somlo, G; Synold, T; Twardowski, P; Yen, Y | 1 |
| Alberti, D; Arzoomanian, RZ; Bailey, H; Berlin, JD; Binger, K; Feierabend, C; Marrocha, R; Morgan-Meadows, S; Mulkerin, D; Thomas, JP; Volkman, J; Wilding, G | 1 |
| Clippe, C; Ligneau, B; Trillet-Lenoir, V | 1 |
| Mornex, F | 1 |
| Budd, GT; Bukowski, RM; Elson, P; Hutson, TE; Mekhail, T; Olencki, T; Peereboom, D; Pelley, R; Srkalovic, G | 1 |
| Blackstock, AW; Lawrence, TS; McGinn, C | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Marselos, M; Mavroudis, D; Nikolaidou, M; Pappas, P; Samonis, G; Souglakos, J; Vardakis, N | 1 |
| Colowick, AB; Fleishman, A; Glaspy, JA; Jadeja, JS; Justice, G; Rossi, G | 1 |
| Butzbach, D; Cairdella, M; Capanna, T; DiPaola, RS; Dvorzhinski, D; Eid, J; Goodin, S; Rubin, E; Shih, JW; Todd, MB; Toppmeyer, D | 1 |
| al-Jazayrly, G; Edelman, MJ; Gandara, DR; Houston, J; Lara, PN; Lau, DH; Lauder, I; Lim, N; Tanaka, M | 1 |
| de Pooter, CM; Korst, AE; Lambrechts, HA; Lardon, F; Pattyn, GG; Pauwels, B; Vermorken, JB | 1 |
| Haigentz, M; Hamilton, A; Hochster, H; Kim, M; Lee, J; Macapinlac, M; Mirchandani, D; Muggia, FM; Pavlick, A; Sewak, S; Sorich, J; Volm, M | 1 |
| Castellano, D; Ciruelos, E; Colomer, R; Cortés-Funes, H; Hitt, R | 1 |
| Flaherty, KT; Hahn, SM; O'Dwyer, PJ; Redlinger, M; Stevenson, JP | 1 |
| Kitchell, BE; Moore, AS | 1 |
| Cerretani, D; Correale, P; Francini, G; Giorgi, G; Marsili, S; Messinese, S; Petrioli, R; Pinto, E; Pozzessere, D; Roviello, F; Sabatino, M | 1 |
| Adjei, AA; Alberts, SR; Atherton, P; Bruzek, LM; Croghan, GA; Erlichman, C; Goldberg, RM; Hanson, LJ; Kaufmann, SH; Marks, RS; Palmer, PA; Pitot, HC; Reid, JM; Sloan, JA; Thibault, A | 1 |
| Behrns, K; Bernard, SA; Calvo, B; Cance, W; Churchel, MA; Detterbeck, FC; Koruda, M; Ollila, D; Poole, ME; Weissler, MC | 1 |
| Chen, A; Grem, JL; Hamilton, JM; Harold, N; Keith, B; Monahan, BP; Morrison, G; Nguyen, D; Pang, J; Quinn, MG; Rowedder, A; Takimoto, CH; Xu, Y | 1 |
| Chen, WR; Hamilton, SA; Ishmael, DR; Liu, H; Nordquist, RE | 1 |
| Bulgaru, A; Egorin, M; Goel, S; Harvey, E; Hochster, H; Ivy, P; Leibes, L; Lockwood, G; Mani, S; Muggia, F; Renshaw, G; Wadler, S; Zamboni, W | 1 |
| Eckhardt, SG; Gentner, L; Goetz, A; Hammond, LA; Izbicka, E; McCreery, H; Mori, M; Patnaik, A; Richards, H; Rowinsky, EK; Rybak, ME; Schwartz, G; Takimoto, CH; Terada, K; Tolcher, AA; Zhang, S | 1 |
| Lee, SJ; Millikan, RE; Mueller, P; Thall, PF | 1 |
| Blackman, MR; Grem, J; Mansky, PJ; Monahan, BP; Wallerstedt, DB | 1 |
| Lawrence, TS | 1 |
| Li, M; Rinehart, JJ; Wang, H; Zhang, R | 1 |
| Alfonso, R; Averbuch, S; Fandi, A; Giaccone, G; González-Larriba, JL; Martens, M; Peters, GJ; Smit, EF; Smith, R; van der Vijgh, WJ; van Oosterom, AT | 1 |
| Algazy, KM; Flaherty, KT; Giatonio, B; O'Dwyer, PJ; Redlinger, M; Stevenson, JP | 1 |
| Clairmont, C; Doroshow, J; Fishman, M; Johnson, B; Margolin, K; Sullivan, D; Sznol, M; Yen, Y | 1 |
| Delaloge, S; Di Palma, M; Forgue, ST; Le Chevalier, T; Llombart, A; Ni, L; Tourani, JM; Turpin, F | 1 |
| Ames, MM; Holcenberg, J; Krailo, MD; Kuttesch, J; Qu, W; Reid, JM; Safgren, SL; Seibel, NL | 1 |
| Dafni, U; Dimopoulos, MA; Dimopoulou, I; Efstathiou, E; Kastritis, E; Lyberopoulos, P; Moulopoulos, LA; Papadimitriou, C; Roussos, C; Samakovli, A | 1 |
| Adams, N; Cunningham, CC; MacEachern, JB; Nemunaitis, J; Paulson, AS; Rich, D; Ruxer, RL; Vukelja, S | 1 |
| Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
| Fan, Y; Fang, L; Lin, NM; Ma, SL; Zeng, S; Zhong, HJ | 1 |
| Cass, CE; Eriksson, S; Mani, RS; Usova, EV | 1 |
| Leen, R; Van Gennip, AH; Van Kuilenburg, AB; Verschuur, AC | 1 |
| Bergman, AM; Hendriks, HR; Kuiper, CM; Myhren, F; Peters, GJ; Sandvold, ML | 1 |
| Korst, AE; Lardon, F; Pauwels, B; Vermorken, JB | 1 |
| Azria, D; Coelho, M; Culine, S; Dubois, JB; Larbouret, C; Lemanski, C; Pèlegrin, A; Serre, A; Ychou, M | 1 |
| Beinert, T; Flath, B; Possinger, K; Schmid, P; Schweigert, M; Sezer, O | 1 |
| Adjei, AA; Alberts, SR; Atherton, PJ; Burch, PA; Dy, GK; Erlichman, C; Goldberg, RM; Hanson, LJ; Pitot, HC; Reid, JM; Rubin, J; Sloan, JA; Suri, A | 1 |
| Algayres, JP; Artru, P; Béchade, D; Bredin, C; Brézault, C; Chaussade, S; Coutant, G; de Gramont, A; Defuentes, G; Desramé, J; Dourthe, LM; Duvic, C; Poirier, JM | 1 |
| Furuse, J; Hasegawa, R; Ikeda, M; Ishii, H; Kaniwa, N; Kikura-Hanajiri, R; Kim, SR; Okusaka, T; Ozawa, S; Saijo, N; Saito, Y; Sawada, J; Sugiyama, E; Ueno, H; Yamamoto, N; Yonemori, K; Yoshida, T | 1 |
| Lippman, AJ | 1 |
| Eklund, JW; Mulcahy, MF; Trifilio, S | 1 |
| Alice Miller, M; Pearce, HL | 1 |
| Blanco-Aparicio, C; Carnero, A; Fominaya, J; Leal, JF; Moneo, V; Pequeño, B; Romero, L; Velasco, J | 1 |
| Beijnen, JH; Crul, M; Howes, A; Pluim, D; Schellens, JH; Siegel-Lakhai, WS; Solanki, B; Sparidans, RW; Zhang, S | 1 |
| Ashley, RA | 1 |
| Carducci, M; Huie, M; Izquierda, M; Liu, G; Marnocha, R; Thomas, J; Wilding, G | 1 |
| Brown, S; Chen, EX; Chin, SF; Duran, I; Nottage, M; Oza, AM; Pond, GR; Siu, LL; Sturgeon, J | 1 |
| Cebon, J; Davis, ID; de Souza, P; Galettis, P; Gan, HK; Links, M; Mitchell, PL | 1 |
| Awada, A; Giannaris, T; Lathia, C; Moore, MJ; Petrenciuc, O; Piccart, M; Schwartz, B; Siu, LL; Takimoto, CH | 1 |
| Corti, A; Curnis, F; Gallo-Stampino, C; Gasparri, A; Sacchi, A; Toma, S | 1 |
| Appleman, LJ; Demetri, GD; Desai, J; George, S; Manola, J; Paul Eder, J; Ryan, DP | 1 |
| Gasparro, S; La Cesa, A; Santini, D; Schiavon, G; Tonini, G; Vincenzi, A; Vincenzi, B | 1 |
| Bartolini, S; Cappuzzo, F; Finocchiaro, G; Gioia, V; Toschi, L | 1 |
| Avritscher, EB; Bekele, BN; Cooksley, CD; Elting, LS; Jones, JA; Michelet, M | 1 |
| Carr, RA; de Vos, FY; Eskens, FA; Gietema, JA; Groen, HJ; Hoekstra, R; Humerickhouse, RA; Knight, RA; Loos, WJ; Uges, DR; van der Gaast, A | 1 |
| Airoldi, M; Cattel, L; Delprino, L; Milla, P; Passera, R; Pedani, F | 1 |
| Danesi, R; Del Tacca, M; Giovannetti, E; Mey, V; Nannizzi, S; Pasqualetti, G | 1 |
| Barzon, L; Cartei, G; Colombrino, E; Nadai, M; Palù, G; Palumbo, M; Richter, SN; Trestin, A | 1 |
| Adjei, AA | 1 |
| Caciagli, B; Landini, I; Mazzei, T; Mini, E; Nobili, S | 1 |
| Furuse, J; Ikeda, M; Ishii, H; Kamatani, N; Kaniwa, N; Kim, SR; Maekawa, K; Minami, H; Morizane, C; Okusaka, T; Ozawa, S; Saijo, N; Saito, Y; Sawada, J; Sugiyama, E; Ueno, H; Yamamoto, N; Yoshida, T | 1 |
| Schultze, JL | 1 |
| Boos, J; Gerss, J; Paulussen, M; Stoffregen, C; Vieira Pinheiro, JP; Wagner-Bohn, A | 1 |
| Huang, HB; Lin, PL; Lin, ZC; Liu, T; Zhong, JT | 1 |
| Appleman, LJ; Clark, JW; Cusack, J; Eder, JP; Enzinger, PC; Fidias, P; Fishman, M; Kashala, O; Lynch, T; Ryan, DP; Supko, JG; Zhu, AX | 1 |
| Chow, W; Doroshow, J; Frankel, P; Gandara, D; Juhasz, A; Lenz, HJ; Leong, L; Lim, D; Margolin, K; Morgan, R; Newman, E; Shibata, S; Somlo, G; Synold, T; Yen, Y | 1 |
| Georgoulias, V; Marselos, M; Mavroudis, D; Nikolaidou, M; Pappas, P | 1 |
| DeVita, VT | 1 |
| El-Rayes, BF; Gadgeel, S; Lorusso, P; Manza, S; Philip, PA; Shields, AF | 1 |
| Leoni, V; Rocci, L; Santini, D; Tonini, G; Vincenzi, B; Virzí, V | 1 |
| Furuse, J; Hasegawa, R; Ishii, H; Kamatani, N; Kaniwa, N; Kikura-Hanajiri, R; Kim, SR; Maekawa, K; Okusaka, T; Ozawa, S; Saijo, N; Saito, Y; Sawada, J; Sugiyama, E; Ueno, H; Yoshida, T | 1 |
| Benninger-Döring, G; Boos, J; Ripkens-Reinhard, A; Wagner-Bohn, A | 1 |
| Antonia, S; Chiappori, A; de Lima Lopes, G; Haura, E; Langevin, M; Lush, R; Rocha-Lima, CM; Simon, G; Sullivan, D | 1 |
| Cusimano, L; Li, M; Saif, MW; Sellers, S; Wang, H; Wang, W; Zhang, R | 1 |
| Aghajanian, C; Chi, DS; Colevas, AD; Derosa, F; Dizon, D; Dupont, J; Hensley, ML; Sabbatini, P; Spriggs, D; Venkatraman, E | 1 |
| El-Rayes, BF; LoRusso, P; Manza, SG; Philip, PA; Shields, AF; Zalupski, M | 1 |
| Clavel, M; Edzes, HT; Geyssen, GJ; Guastalla, J; Laan, AC; Noordhuis, P; Peters, GJ; Vermorken, JB | 1 |
| Amarantidis, K; Chatzaki, E; Houhouli, K; Kakolyris, S; Lyrantzopoulos, N; Matthaios, D; Miloussis, A; Papatheodorou, K; Tentes, A; Tsaroucha, A | 1 |
| Arnadottir, M; Benediktsson, T; Hrafnkelsson, J | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Giassas, S; Kalykaki, A; Kentepozidis, N; Marselos, M; Mavroudis, D; Nikolaidou, M; Pappas, P; Vamvakas, L | 1 |
| Giaccone, G; Honeywell, R; Kuenen, BC; Peters, GJ; Smit, EF; van de Velde, H; Voortman, J | 1 |
| Füessl, HS | 1 |
| Benhadji, K; Calvo, F; Chiao, J; Cvitkovic, E; Faivre, S; Galmarini, CM; Ghoul, A; Green, SR; Le Tourneau, C; Raymond, E; Serova, M | 1 |
| Agelaki, S; Georgoulias, V; Ignatiadis, M; Kalbakis, K; Kalykaki, A; Karabeazis, A; Karampeazis, A; Mavroudis, D; Saridaki, Z; Sfakiotaki, G; Vamvakas, L; Vardakis, N | 1 |
| Kibble, A | 1 |
| Beerepoot, LV; Beijnen, JH; Enas, N; Mehra, N; Musib, L; Radema, SA; Rademaker-Lakhai, JM; Schellens, JH; van Hal, G; van Maanen, R; Vermaat, JS; Visseren-Grul, CM; Voest, EE; Witteveen, EO | 1 |
| Cao, LM; Huang, FY; Jiao, CL; Wu, RL; Zheng, SJ; Zheng, SP | 1 |
| Thachil, J | 1 |
| Agelaki, S; Georgoulias, V; Gioulbasanis, I; Ignatiadis, M; Karampeazis, A; Kentepozidis, N; Mavroudis, D; Papadimitraki, E; Vamvakas, L; Vardakis, N | 1 |
| Bay, JO; Spano, JP | 1 |
| Fornier, MN; Hudis, C; Kelsen, DP; Lefkowitz, R; O'Reilly, E; Patil, S; Rathkopf, D; Schwartz, GK; Shah, M; Tse, AN | 1 |
| Ali, Y; Egorin, MJ; Gharibo, MM; Gounder, MK; Lagattuta, TF; Lin, Y; Poplin, EA; Rubin, EH; Stein, MN | 1 |
| Dudek, AZ; Keshtgarpour, M; Kumar, P; Larson, T | 1 |
| Ciccolini, J; Evrard, A; Mercier, C | 1 |
| Aldaz, A; Aramendía, JM; Aristu, J; Centeno, C; Hernández, M; Moreno, M; Nieto, Y; Pérez-Calvo, J; Rifón, J; Sayar, O; Viteri, S; Viúdez, A; Zafra, A; Zufia, L | 1 |
| Galettis, P; Jiang, X; Links, M; McLachlan, AJ; Mitchell, PL | 1 |
| George, TJ; Rajasekhar, A | 1 |
| Broaddus, VC; Hassan, R; Liewehr, DJ; Wilson, S; Zhang, J | 1 |
| Miller, JD | 1 |
| Gandhi, V | 1 |
| de Souza, PL; Galettis, P; Grimison, P; Jelinek, M; Liauw, W; Links, MJ; Manners, S; Metharom, E | 1 |
| Alberti, D; Bailey, H; Brandon, H; Eickhoff, J; Holen, K; Morgan-Meadows, S; Oliver, K; Schelman, W; Thomas, JP; Wilding, G | 1 |
| Marik, PE; Vahid, B | 1 |
| Cartei, G; Labianca, R | 1 |
| Arpicco, S; Canal, F; Dalla Via, L; Pasut, G; Schiavon, O; Veronese, FM | 1 |
| Beijnen, JH; Schellens, JH; Veltkamp, SA | 1 |
| Brown, JA; Fowler, JD; Johnson, KA; Suo, Z | 1 |
| Brahmer, J; Donehower, RC; Elsayed, Y; Ettinger, D; Hidalgo, M; Jimeno, A; Khan, Y; Laheru, D; Lansey, D; Messersmith, WA; Zannikos, P | 1 |
| Couvreur, P; Reddy, LH | 1 |
| Calabresi, F; Ceribelli, A; Crecco, M; Pollera, CF | 1 |
| Brown, TD; Burris, HA; Craig, JB; Havlin, K; Kuhn, JG; O'Rourke, TJ; Satterlee, WG; Tarassoff, PG; Von Hoff, DD | 1 |
| Abonyi, M; Hata, Y; Look, KY; Prajda, N; Singhal, RL; Szekeres, T; Weber, G; Yeh, A | 1 |
| Hansen, HH; Kristjansen, PE; Lund, B | 1 |
| Bamberger, U; Boven, E; Feller, N; Jansen, WJ; Pinedo, HM; van der Wilt, CL | 1 |
| Martin, C; Mosconi, AM; Tonato, M | 1 |
| Pronk, LC; Schellens, JH; Verweij, J | 1 |
| Drengler, R; Eckardt, J; Eckhardt, G; Villalona-Calero, M; Von Hoff, D | 1 |
| Anderson, H; Lund, B; Martin, C; Thatcher, N | 1 |
| Cheson, BD; Phillips, PH; Sorensen, JM | 1 |
| Hanauske, AR | 1 |
| Von Hoff, DD | 2 |
| Abbruzzese, JL | 1 |
| Green, MR | 2 |
| Lawrence, TS; Shewach, DS | 1 |
| Fukuoka, M; Furuse, K; Hasegawa, K; Hirabayashi, K; Nakajima, H; Niitani, H; Noda, K; Ogura, T; Taguchi, T | 1 |
| Mani, S; Ratain, MJ | 1 |
| Hui, YF; Reitz, J | 1 |
| Bergman, AM; Guechev, A; Peters, GJ; Postmus, PE; van Moorsel, CJ; Veerman, G; Vermorken, JB | 1 |
| Calabresi, F; Ceribelli, A; Crecco, M; Oliva, C; Pollera, CF | 1 |
| Bokemeyer, C; Daikeler, T; Hartmann, JT; Kanz, L; Maas, K | 1 |
| Awada, A; Klastersky, J | 1 |
| Eda, H; Foley, LH; Ishitsuka, H; Keith, DD; Miwa, M; Ouchi, KF; Ura, M | 1 |
| Brand, R; Capadano, M; Tempero, M | 1 |
| Kinsella, AR; Smith, D | 1 |
| Aapro, MS; Hatty, S; Martin, C | 1 |
| Carmichael, J | 1 |
| Aylesworth, C; Burris, HA; Eckardt, JR; Eckhardt, SG; Forral, K; Kraynak, MA; Nicol, SJ; Rinaldi, DA; Rodriguez, GI; Rothenberg, ML; Sharma, A; Stephens, CD; Villalona-Calero, MA; Von Hoff, DD; Weiss, GR | 1 |
| Abbruzzese, JL; Gravel, D; Plunkett, W; Raber, MN; Touroutoglou, N | 1 |
| Karlsson, G; Ragnarson Tennvall, G | 1 |
| Steward, WP; Thomas, A | 1 |
| Kroep, JR; Peters, GJ; Pinedo, HM; Postmus, PE; van der Vijgh, WJ; van Groeningen, CJ; van Moorsel, CJ; Veerman, G; Vermorken, JB; Voorn, DA | 1 |
| Arlauskas, P; Ibrahim, D; Philip, PA; Shields, A; Zalupski, M | 1 |
| Höffken, K; Kath, R; Sauer-Heilborn, A; Schneider, CP | 1 |
| Baldwin, SA; Cass, CE; Karpinski, E; Mackey, JR; Smith, KM; Yao, SY; Young, JD | 1 |
| Eisbruch, A; Fields, MT; Lawrence, TS; McGinn, CJ; Shewach, DS | 1 |
| Grant, S; Poplin, E; Roberts, J; Rubin, E; Tombs, M | 1 |
| Adjei, AA; Erlichman, C | 1 |
| Baccala, P; Berg, D; Clark, JW; Finkelstein, D; Fuchs, CS; Grenon, N; Grossbard, ML; Lynch, TJ; Mayer, RJ; Ryan, DP; Seiden, MV | 1 |
| Armand, JP; Baudin, E; Boige, V; Chaouche, M; Chouaki, N; Delord, JP; Ducreux, M; Escudier, B; Faivre, S; Kayitalire, L; Le Chevalier, T; Pautier, P; Raymond, E; Rixe, O; Rodier, JM; Ruffie, P | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N | 1 |
| Bamberg, M; Brandes, A; Plasswilm, L; Reichmann, U | 1 |
| Adjei, AA; Alberts, SR; Atherton, P; Erlichman, C; Goldberg, RM; Hanson, LJ; Jett, J; Peethambaram, P; Pitot, HC; Reid, JM; Sloan, JA | 1 |
| Bishop, J; Boyer, M; Davison, J; Emmett, E; McClure, B; Michael, M; Millward, M; Rischin, D; Smith, J; Zalcberg, J | 1 |
| Budman, D; Byrd, J; Egorin, MJ; Hawkins, M; Hohl, R; Hollis, D; Mani, S; Meropol, NJ; Ratain, MJ; Rosner, GL; Venook, AP | 1 |
| Mitchell, PL | 1 |
| Sone, S | 1 |
| Drengler, RL; Eckhardt, SG; Felton, SA; Garner, AM; Hammond, LA; Hidalgo, M; Mallikaarjun, S; Patnaik, A; Rowinsky, EK; Siu, LL; Tammara, BK; Von Hoff, DD | 1 |
| Brescia, FJ; Green, MR; Rocha Lima, CM; Sherman, CA; Urbanic, JJ | 1 |
| Doyle, TH; McKenna, WG; Mornex, F | 1 |
| Giaccone, G; Pinedo, HM; Savonije, JH; Spanier, BW; van Groeningen, CJ | 1 |
| Adjei, AA; Alberts, SR; Atherton, PJ; Burch, PA; Erlichman, C; Goldberg, RM; Kaufmann, SH; Okuno, SH; Pitot, HC; Rubin, J; Sloan, J | 1 |
| Botwood, N | 1 |
| Algazy, K; Gallagher, M; Giantonio, B; Haller, D; O'Dwyer, PJ; Raskay, BJ; Stevenson, JP; Sun, W; Vaughn, D | 1 |
| Bhargava, P; Dahut, W; Figuera, M; Fried, K; Gehan, E; Hanfelt, J; Hawkins, MJ; Lefebvre, P; Marshall, JL; Rizvi, NA; Williams, M | 1 |
| Johansson, M; Karlsson, A; Sanda, A; Zhu, C | 1 |
| Alonso, V; Antón, A; Artal, A; Herrero, A; Martinez-Trufero, J; Maurel, J; Puertas, MM; Puertolas, T; Zorrilla, M | 1 |
| Lawrence, TS; McGinn, CJ | 1 |
| Bertucci, D; Mani, S; Ratain, MJ; Schilsky, RL; Stadler, WM; Vogelzang, NJ | 1 |
| Bertucci, D; Kindler, HL; Ratain, MJ; Schilsky, RL; Vogelzang, NJ | 1 |
| Arcangeli, V; Drudi, G; Fochessati, F; Gianni, L; Mianulli, AM; Oliverio, G; Panzini, I; Pasini, G; Pasquini, E; Ravaioli, A; Sartori, S; Tassinari, D | 1 |
| Cropp, GF; Giaccone, G; Hoekman, K; Huisman, H; Kedde, MA; Kuenen, BC; Levi, M; Noordhuis, P; Parson, MR; Peters, GJ; Pinedo, HM; Rosen, L; Ruijter, R; Scigalla, P; Smit, EF; van der Vijgh, WJ | 1 |
| Böttcher, HD; Brady, LW; Class, R; Mose, S; Oszvald, A; Rahn, A; Weber, HW | 1 |
| Azria, D; Culine, S; Dubois, JB; Jacot, W; Lemanski, C; Prost, P; Ychou, M | 1 |
| Singhal, RL; Szekeres, T; Weber, G; Yeh, YA | 1 |
| Baker, L; Corbett, T; Flaherty, L; Poplin, EA; Redman, BG; Tarasoff, P; Valdivieso, M | 1 |
| Brown, TD; Burris, HA; Havlin, KA; O'Rourke, TJ; Rodriguez, GI; Wall, JG; Weiss, GR | 1 |
| Abbruzzese, JL; Grunewald, R; Plunkett, W; Tarassoff, P | 1 |
| Abbruzzese, JL; Adams, T; Gravel, D; Grunewald, R; Mineishi, S; Nowak, B; Raber, MN; Satterlee, W; Tarassoff, P; Weeks, EA | 1 |
87 review(s) available for gemcitabine and Benign Neoplasms
| Article | Year |
|---|---|
Biotin conjugated organic molecules and proteins for cancer therapy: A review.
Topics: Antineoplastic Agents; Biotin; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neoplasms; Organic Chemicals; Proteins; Structure-Activity Relationship | 2018 |
Multi-target compounds acting in cancer progression: Focus on thiosemicarbazone, thiazole and thiazolidinone analogues.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Disease Progression; Drug Delivery Systems; Drug Discovery; Humans; Intracellular Signaling Peptides and Proteins; Neoplasms; Thiazoles; Thiazolidines; Thiosemicarbazones | 2019 |
Novel strategies to improve tumour therapy by targeting the proteins MCT1, MCT4 and LAT1.
Topics: Antineoplastic Agents; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Large Neutral Amino Acid-Transporter 1; Molecular Structure; Monocarboxylic Acid Transporters; Muscle Proteins; Neoplasms; Symporters | 2021 |
Small Molecular Gemcitabine Prodrugs for Cancer Therapy.
Topics: Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Prodrugs | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action.
Topics: Cytarabine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoplasms; Phosphorylation; Prodrugs; Pyrimidines | 2020 |
Gemcitabine Peptide-Based Conjugates and Their Application in Targeted Tumor Therapy.
Topics: Animals; Cell-Penetrating Peptides; Deoxycytidine; Gemcitabine; Humans; Molecular Targeted Therapy; Nanoparticles; Neoplasms; Peptides | 2021 |
Lessons Learned from Gemcitabine: Impact of Therapeutic Carrier Systems and Gemcitabine's Drug Conjugates on Cancer Therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Neoplasms | 2017 |
[What is the place of the combinations for immunotherapy with chemotherapy or with other immune checkpoint inhibitors?]
Topics: Anthracyclines; Antigens, Neoplasm; Antineoplastic Agents; Combined Modality Therapy; CTLA-4 Antigen; Cyclophosphamide; Deoxycytidine; Gemcitabine; Humans; Immune Tolerance; Immunotherapy; Neoplasms; Platinum Compounds; Programmed Cell Death 1 Receptor; Taxoids | 2017 |
Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Cytidine Triphosphate; Deoxycytidine; Gemcitabine; Humans; Neoplasms | 2017 |
Fluorinated nucleosides as an important class of anticancer and antiviral agents.
Topics: Antineoplastic Agents; Antiviral Agents; Deoxycytidine; Fluorine; Fluorouracil; Gemcitabine; HIV; Neoplasms; Nucleoside Transport Proteins; Nucleosides; Positron-Emission Tomography | 2017 |
Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles.
Topics: Antineoplastic Agents; Deoxycytidine; Drug Carriers; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lipids; Lysosomes; Nanomedicine; Nanoparticles; Neoplasms | 2018 |
Cancer Targeting and Drug Delivery Using Carbon-Based Quantum Dots and Nanotubes.
Topics: Antineoplastic Agents; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Liberation; Fluorescent Dyes; Folic Acid; Gemcitabine; Humans; Hyaluronic Acid; Molecular Targeted Therapy; Nanotubes, Carbon; Neoplasms; Quantum Dots; Surface Properties; Transferrin | 2018 |
Latest developments in MUC1 immunotherapy.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Glycosylation; Humans; Immunotherapy; Mucin-1; Neoplasms; Tumor Microenvironment | 2018 |
The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Chloroquine; Clinical Trials as Topic; Dacarbazine; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Hydroxychloroquine; Neoplasms; Risk; Temozolomide; Treatment Outcome | 2018 |
RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Biological Availability; Cytidine; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Patient Selection | 2019 |
Risk of venous and arterial thromboembolic events in cancer patients treated with gemcitabine: a systematic review and meta-analysis.
Topics: Antimetabolites, Antineoplastic; Arterial Occlusive Diseases; Deoxycytidine; Gemcitabine; Humans; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Risk; Venous Thromboembolism | 2013 |
Increased risk of high-grade hemorrhage in cancer patients treated with gemcitabine: a meta-analysis of 20 randomized controlled trials.
Topics: Deoxycytidine; Gemcitabine; Hemorrhage; Humans; Incidence; Neoplasms; Publication Bias; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2013 |
Methods of biological network inference for reverse engineering cancer chemoresistance mechanisms.
Topics: Antineoplastic Agents; Bayes Theorem; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Neoplasms; Pancreatic Neoplasms; Stochastic Processes | 2014 |
The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunity, Cellular; Immunologic Factors; Interleukin-1beta; Neoplasms; Th17 Cells | 2014 |
[Impact of chemotherapies on immunosuppression and discovery of new therapeutic targets].
Topics: Animals; Carrier Proteins; CD4-Positive T-Lymphocytes; Deoxycytidine; Epoxy Compounds; Fluorouracil; Gemcitabine; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Inflammasomes; Interleukin-17; Interleukin-1beta; Mice; Myeloid Cells; Neoplasms; Neovascularization, Pathologic; NLR Family, Pyrin Domain-Containing 3 Protein; Tyrosine | 2014 |
Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.
Topics: Alleles; Antimetabolites, Antineoplastic; Chemotherapy-Induced Febrile Neutropenia; Cytidine Deaminase; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Genetic Markers; Humans; Male; MEDLINE; Neoplasm Proteins; Neoplasms; Polymorphism, Genetic; Survival Rate | 2015 |
Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Cyclophosphamide; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Killer Cells, Natural; Neoplasms; Paclitaxel; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tumor Escape; Tumor Microenvironment | 2015 |
Integrative meta-analysis of multiple gene expression profiles in acquired gemcitabine-resistant cancer cell lines to identify novel therapeutic biomarkers.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Neoplasms; Oligonucleotide Array Sequence Analysis; Protein Interaction Maps | 2015 |
Thrombotic microangiopathy, cancer, and cancer drugs.
Topics: Adrenal Cortex Hormones; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Immunosuppressive Agents; Kidney; Male; Neoplasms; Pancreatic Neoplasms; Plasmapheresis; Thrombotic Microangiopathies; Vascular Endothelial Growth Factor A | 2015 |
Managing thrombocytopenia associated with cancer chemotherapy.
Topics: Antineoplastic Agents; Benzoates; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Evidence-Based Medicine; Gemcitabine; Humans; Hydrazines; Neoplasms; Platelet Count; Platelet Transfusion; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoiesis; Thrombopoietin; Treatment Outcome | 2015 |
Antineoplastic agents and thrombotic microangiopathy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Immunologic Factors; Incidence; Interferon-alpha; Mitomycin; Molecular Targeted Therapy; Neoplasms; Proteasome Inhibitors; Signal Transduction; Thrombotic Microangiopathies; Vascular Endothelial Growth Factor A | 2017 |
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective.
Topics: Adult; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Precision Medicine | 2016 |
Combination of metformin with chemotherapeutic drugs via different molecular mechanisms.
Topics: Androgen Antagonists; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Estrogen Receptor Modulators; Fluorouracil; Gemcitabine; Humans; Metformin; Methotrexate; Neoplasms; Paclitaxel; Tubulin Modulators | 2017 |
Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Combined Modality Therapy; Deoxycytidine; Drug Delivery Systems; ErbB Receptors; Gemcitabine; Humans; Models, Biological; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Radiation-Sensitizing Agents | 2008 |
Gemcitabine: vascular toxicity and prothrombotic potential.
Topics: Animals; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Risk Factors; Thrombosis; Vascular Diseases | 2008 |
[Biological basis of chemo-radiotherapy associations].
Topics: Cell Proliferation; Cisplatin; Combined Modality Therapy; Dacarbazine; Deoxycytidine; DNA Damage; DNA Repair; Fluorouracil; Gemcitabine; Humans; Neoplasms; Oxygen Consumption; Radiation Tolerance; Temozolomide | 2009 |
Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Male; Mitoxantrone; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Taxoids; Virus Replication | 2009 |
Pharmacogenetics and pharmacoepigenetics of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Epigenomics; Gemcitabine; Humans; Neoplasms; Pharmacogenetics | 2010 |
[Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Deoxycytidine; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
PARP inhibition: PARP1 and beyond.
Topics: Animals; Antineoplastic Agents; Cell Death; Dacarbazine; Deoxycytidine; DNA Damage; DNA, Neoplasm; Gemcitabine; Humans; Kinetics; Mice; Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Substrate Specificity; Temozolomide | 2010 |
Salirasib in the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Membrane; Clinical Trials, Phase I as Topic; Deoxycytidine; Disease-Free Survival; Drug Screening Assays, Antitumor; Farnesol; Farnesyltranstransferase; Galectins; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Middle Aged; Neoplasm Proteins; Neoplasms; Pancreatic Neoplasms; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Salicylates; Signal Transduction | 2010 |
Targeting Notch signaling pathway to overcome drug resistance for cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; MicroRNAs; Neoplasms; Paclitaxel; Receptors, Notch; Signal Transduction; Tamoxifen; Taxoids; Trastuzumab | 2010 |
Gemox: a widely useful therapy against solid tumors-review and personal experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Drug Synergism; Gemcitabine; Humans; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy | 2010 |
Integrating pharmacogenetics into gemcitabine dosing--time for a change?
Topics: Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Pharmacogenetics; Precision Medicine; Prognosis | 2011 |
Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung; Neoplasms; Regression Analysis; Taxoids | 2011 |
Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Liposomes; Nanoparticles; Neoplasms; Polymers; Squalene; Tissue Distribution | 2011 |
Role of myeloid-derived suppressor cells in tumor immunotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Myeloid Cells; Neoplasms; T-Lymphocytes, Regulatory | 2012 |
Gemcitabine: a critical nucleoside for cancer therapy.
Topics: Antimetabolites, Antineoplastic; Catalytic Domain; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Humans; Models, Molecular; Neoplasms; Nucleosides; Phosphorylation | 2012 |
Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Forecasting; Gemcitabine; Humans; Liposomes; Nanocapsules; Nanomedicine; Neoplasms | 2012 |
[Role of gemcitabine in the treatment of other malignant tumors].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Female; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Melanoma; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Outcome; Uterine Cervical Neoplasms | 2002 |
[Combined gemcitabine and radiotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; Maximum Tolerated Dose; Multicenter Studies as Topic; Neoplasms; Neoplasms, Experimental; Otorhinolaryngologic Neoplasms; Pancreatic Neoplasms; Prodrugs; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy; Tumor Cells, Cultured | 2002 |
The mechanism of action of radiosensitization of conventional chemotherapeutic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Floxuridine; Fluorouracil; Gemcitabine; Humans; Neoplasms; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Risk Factors | 2003 |
New chemotherapy agents in veterinary medicine.
Topics: Animals; Antineoplastic Agents; Cat Diseases; Cats; Deoxycytidine; Dog Diseases; Dogs; Gemcitabine; Ifosfamide; Lomustine; Mesna; Neoplasms; Streptozocin; Veterinary Drugs | 2003 |
Radiation sensitizers and targeted therapies.
Topics: Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Neoplasms; Radiation-Sensitizing Agents | 2003 |
Combined modality therapy of gemcitabine and radiation.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; DNA; DNA Damage; DNA Repair; Gemcitabine; Humans; Neoplasms; Radiation-Sensitizing Agents; Rodentia; Tumor Cells, Cultured | 2005 |
[Concomitant use of radiotherapy and gemcitabine: preclinical findings and clinical practice].
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mice; Neoplasms; Otorhinolaryngologic Neoplasms; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Rats; Time Factors; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 2004 |
[Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Neoplasms; Prognosis; Retrospective Studies | 2005 |
Chemotherapy dosing in the setting of liver dysfunction.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Liver; Liver Diseases; Liver Function Tests; Male; Maximum Tolerated Dose; Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Topotecan | 2005 |
Role of gemcitabine in cancer therapy.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Interactions; Female; Gemcitabine; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms | 2005 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colorectal Neoplasms; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Incidence; Lung Neoplasms; Lymphoma, Non-Hodgkin; Mucositis; Neoplasms; Prednisone; Radiotherapy; Severity of Illness Index; Stomatitis; Taxoids; Vinblastine; Vincristine; Vinorelbine | 2006 |
In vitro studies on gemcitabine combinations with other antiblastics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Evaluation, Preclinical; Drug Interactions; Gemcitabine; Humans; Models, Biological; Neoplasms; Prodrugs; Tumor Cells, Cultured | 2006 |
Clinical studies of pemetrexed and gemcitabine combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Models, Biological; Neoplasms; Pancreatic Neoplasms; Pemetrexed | 2006 |
Cellular pharmacology of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Deoxycytidine; Gemcitabine; Humans; Models, Biological; Neoplasms | 2006 |
[Requirements for the development of molecularly defined targeted therapy in oncology].
Topics: Algorithms; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Bevacizumab; Biomedical Research; Biotechnology; Breast Neoplasms; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Computational Biology; Controlled Clinical Trials as Topic; Deoxycytidine; Drug Industry; Female; Gemcitabine; Genome, Human; Humans; Imatinib Mesylate; Medical Oncology; Molecular Biology; Multicenter Studies as Topic; Neoplasms; Phenotype; Piperazines; Practice Guidelines as Topic; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Risk Assessment; Trastuzumab; Treatment Outcome | 2006 |
Implementing Good Clinical Practice in two noncommercial phase II studies in children with cancer.
Topics: Child; Clinical Trials, Phase II as Topic; Deoxycytidine; European Union; Financing, Government; Gemcitabine; Germany; Humans; Informed Consent; Medical Oncology; Neoplasms; Pediatrics; Practice Guidelines as Topic; Practice Patterns, Physicians' | 2007 |
Pulmonary complications of novel antineoplastic agents for solid tumors.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Deoxycytidine; Doxorubicin; Epirubicin; Etoposide; Everolimus; Gemcitabine; Humans; Lung; Lung Diseases; Mitoxantrone; Neoplasms; Pneumonia; Pyrimidines; Risk Factors; Sirolimus; Teniposide; Trastuzumab | 2008 |
Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Infusions, Intravenous; Neoplasms; Time Factors | 2008 |
Novel approaches to deliver gemcitabine to cancers.
Topics: Animals; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Gemcitabine; Humans; Neoplasms | 2008 |
Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine).
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Drug Evaluation; Drug Evaluation, Preclinical; Gemcitabine; Humans; Neoplasms; Neoplasms, Experimental | 1993 |
Safety profile of gemcitabine.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blood Cell Count; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Edema; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasms | 1995 |
Emerging drug treatments for solid tumours.
Topics: Amifostine; Antineoplastic Agents; Aziridines; Deoxycytidine; Gemcitabine; Humans; Indolequinones; Indoles; Neoplasms; Organoplatinum Compounds; Paclitaxel; Protein Kinase C; Topoisomerase I Inhibitors | 1996 |
New anticancer agents in clinical development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Neoplasms; Polysaccharides, Bacterial; Prodrugs; Quinazolines; Tegafur; Thiophenes; Thymidylate Synthase; Uracil | 1995 |
Gemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Kidney Diseases; Lung Neoplasms; Neoplasms; Thrombocytopenia | 1996 |
The development of new chemotherapeutic agents.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Neoplasms; Pemetrexed; Quinazolines; Thiophenes; Trimetrexate | 1996 |
Phase I studies with the novel nucleoside analog gemcitabine.
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase I as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Neoplasms | 1996 |
Gemcitabine safety overview.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Neoplasms | 1996 |
Radiosensitization of human solid tumor cell lines with gemcitabine.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1996 |
Promising new agents in oncologic treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Mice; Microtubules; Neoplasm Proteins; Neoplasms; Paclitaxel; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan | 1996 |
Gemcitabine: a cytidine analogue active against solid tumors.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Neoplasms, Experimental | 1997 |
Combination chemotherapy studies with gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Deoxycytidine; Drug Synergism; Etoposide; Gemcitabine; Humans; Mitomycin; Neoplasms; Ribonucleotide Reductases; Tumor Cells, Cultured | 1997 |
[Gemcitabine: a new chemotherapy agent for solid cancers].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Palliative Care; Pancreatic Neoplasms; Radiation-Sensitizing Agents | 1997 |
Tumor resistance to antimetabolites.
Topics: Antimetabolites, Antineoplastic; Cell Cycle Proteins; Deoxycytidine; DNA Damage; DNA, Neoplasm; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Amplification; Humans; Methotrexate; Mutation; Neoplasms; Quinazolines; Thiophenes | 1998 |
Gemcitabine--a safety review.
Topics: Alopecia; Antimetabolites, Antineoplastic; Blood Cell Count; Bone Marrow; Deoxycytidine; Digestive System; Gemcitabine; Hematuria; Humans; Nausea; Neoplasms; Vomiting | 1998 |
The role of gemcitabine in the treatment of other tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasms | 1998 |
Radiosensitization by gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Combined Modality Therapy; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Ribonucleotide Reductases | 1999 |
[Clinical development of new molecular targeted therapeutics for cancer therapy].
Topics: Angiogenesis Inhibitors; Apoptosis; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Hydroxamic Acids; Neoplasms | 2000 |
Docetaxel followed by gemcitabine and irinotecan in solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Survival Rate; Taxoids | 2001 |
Recent advances in the use of radiosensitizing nucleosides.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease Models, Animal; Fluorouracil; Gemcitabine; Humans; Neoplasms; Radiation-Sensitizing Agents | 2001 |
[Combined radiotherapy and gemcitabine. Evaluation of clinical data based on experimental knowledge].
Topics: Animals; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Neoplasms; Radiography; Radiotherapy, Adjuvant; Treatment Outcome | 2002 |
[Gemcitabine and ionizing radiations: radiosensitization or radio-chemotherapy combination].
Topics: Adenosine Triphosphate; Cell Cycle; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Neoplasms; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2002 |
New anticancer agents.
Topics: Alkaloids; Animals; Antineoplastic Agents; Azacitidine; Biphenyl Compounds; Chrysenes; Deoxycytidine; Echinomycin; Epirubicin; Etanidazole; Flavonoids; Gemcitabine; Guanidines; Humans; Idarubicin; Menogaril; Mitoguazone; Neoplasms; Nitroimidazoles; Nogalamycin; Organoplatinum Compounds; Paclitaxel; Pentostatin; Polymers; Propylene Glycols; Ribavirin; Sulfonylurea Compounds; Trimetrexate; Vidarabine Phosphate | 1991 |
185 trial(s) available for gemcitabine and Benign Neoplasms
| Article | Year |
|---|---|
A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Azepines; Deoxycytidine; Gemcitabine; Humans; Maximum Tolerated Dose; Neoplasms; Pancreatic Neoplasms; Pyrimidines | 2022 |
A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Carboplatin; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Neoplasms, Second Primary | 2022 |
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Gemcitabine; Humans; Lung Neoplasms; Neoplasms; Small Cell Lung Carcinoma | 2023 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Predicting Chemotherapy-Induced Neutropenia and Granulocyte Colony-Stimulating Factor Response Using Model-Based In Vitro to Clinical Translation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Cells, Cultured; Deoxycytidine; Doxorubicin; Filgrastim; Gemcitabine; Humans; Incidence; Models, Biological; Myelopoiesis; Neoplasms; Neutropenia; Paclitaxel; Polyethylene Glycols; Primary Cell Culture; Risk Assessment; Treatment Outcome | 2020 |
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Spermine; Sunitinib | 2021 |
A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors.
Topics: Adult; Aged; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Sulfones | 2021 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa | 2017 |
Phase I study of veliparib in combination with gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasms | 2017 |
Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Deoxycytidine; Female; Gemcitabine; Humans; Hydrazines; Male; Middle Aged; Neoplasms; Pyrazoles; Thrombocytosis | 2017 |
Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Deoxycytidine; Endpoint Determination; Female; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Pyrimidines; Treatment Outcome | 2018 |
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Fatigue; Female; Gemcitabine; Half-Life; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Thrombocytopenia; Treatment Outcome | 2018 |
A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Ergocalciferols; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2018 |
A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Capecitabine; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Prognosis; Quinolones; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Vascular Endothelial Growth Factor; Survival Rate; Tissue Distribution | 2019 |
Highlights of the NCCN Oncology Research Program.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Female; Folate Receptor 1; Gemcitabine; Humans; Immunoconjugates; Male; Maytansine; Neoplasm Recurrence, Local; Neoplasms; Progression-Free Survival; Young Adult | 2019 |
Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sunitinib | 2013 |
A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Demography; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Norbornanes; Protein Kinase Inhibitors; Pyrimidines; Young Adult | 2014 |
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Pyridones; Pyrimidinones; Thrombocytopenia; Treatment Outcome | 2013 |
Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Carboxylesterase; Deoxycytidine; Deoxyuridine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Polymorphism, Single Nucleotide; Prodrugs | 2013 |
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).
Topics: Adult; Aged; Amyloid Precursor Protein Secretases; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Calcium-Binding Proteins; Deoxycytidine; Female; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Male; Membrane Proteins; Middle Aged; Neoplasms; Receptor, Notch1; Receptor, Notch3; Receptors, Notch; Serrate-Jagged Proteins | 2014 |
Use of glucose solution for the alleviation of gemcitabine-induced vascular pain: a double-blind randomized crossover study.
Topics: Adult; Antimetabolites, Antineoplastic; Cross-Over Studies; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Glucose; Humans; Infusions, Parenteral; Male; Middle Aged; Neoplasms; Pain; Pain Measurement; Vascular Diseases | 2013 |
Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Checkpoint Kinase 2; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinases; Protein Serine-Threonine Kinases; Thiophenes; Urea | 2013 |
Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Depsipeptides; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2014 |
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Protein Kinases; Thiophenes; Urea | 2014 |
A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines | 2014 |
Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Everolimus; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Sirolimus | 2014 |
Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Deoxyuridine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Prodrugs; Taxoids; Treatment Outcome | 2014 |
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Treatment Outcome | 2014 |
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Broadly Neutralizing Antibodies; Carboplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Polyethylene Glycols; Taxoids | 2015 |
Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Gemcitabine; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasms; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Cisplatin; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Quinolones; Thromboembolism; Treatment Outcome; Urinary Bladder Neoplasms; Young Adult | 2014 |
Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Hydrazines; Male; Middle Aged; Neoplasm Staging; Neoplasms; Platelet Count; Pyrazoles; Treatment Outcome | 2015 |
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Sulfonamides; Taxoids; Temozolomide; Young Adult | 2015 |
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Pancreatic Neoplasms; Phthalazines; Piperazines; Prognosis; Survival Rate | 2015 |
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Checkpoint Kinase 1; Cohort Studies; Cytarabine; Deoxycytidine; Female; Gemcitabine; Histones; Humans; Infusions, Intravenous; K562 Cells; Male; Melanoma; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Sarcoma; Time Factors | 2015 |
A multicenter, open-label, Phase 1 study evaluating the safety and tolerability of pegaspargase in combination with gemcitabine in advanced metastatic solid tumors and lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Polyethylene Glycols | 2015 |
Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Taxoids | 2015 |
Influence of infusion method on gemcitabine pharmacokinetics: a controlled randomized multicenter trial.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Half-Life; Humans; Infusion Pumps; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Neoplasms; Occupational Exposure; Sodium Chloride; Time Factors | 2015 |
A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Asian People; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gemcitabine; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Pyridones; Pyrimidinones | 2015 |
Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyrazines | 2015 |
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Deoxyuridine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Prodrugs | 2015 |
A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Endometrial Neoplasms; Female; Furans; Gemcitabine; Humans; Ketones; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Neutropenia; Ontario; Ovarian Neoplasms; Response Evaluation Criteria in Solid Tumors; Treatment Outcome | 2015 |
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Fatigue; Female; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Phenylurea Compounds; Pyrazines; Thrombocytopenia; Young Adult | 2016 |
Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Depsipeptides; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lymphoma; Male; Middle Aged; Neoplasms; Niacinamide; Peptides, Cyclic; Phenylurea Compounds; Prospective Studies; Sorafenib; Young Adult | 2017 |
Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Cell Proliferation; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; T-Lymphocytes | 2008 |
A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Kinetics; Lung Neoplasms; Male; Middle Aged; Neoplasms; Time Factors | 2008 |
Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-alpha: a description of a phase I-II protocol.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Hyperthermia, Induced; Interferon-alpha; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quality of Life | 2008 |
Phase-I-study of four different schedules of pemetrexed, gemcitabine and cisplatin in patients with locally advanced or metastatic solid tumours.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pemetrexed; Treatment Outcome; Young Adult | 2008 |
A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Dietary Supplements; Drug Administration Schedule; Female; Folic Acid; Gemcitabine; Glutamates; Guanine; Humans; Maximum Tolerated Dose; Neoplasms; Neutropenia; Ovarian Neoplasms; Pemetrexed; Treatment Outcome; Vitamin B Complex | 2008 |
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome | 2009 |
Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Oligonucleotides | 2008 |
Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Salvage Therapy; Topotecan; Treatment Outcome | 2009 |
A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Fever; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2009 |
Phase I study of fixed dose gemcitabine plus epirubicin in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome | 2009 |
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor | 2009 |
Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Prognosis; Survival Rate | 2009 |
Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Biomarkers, Tumor; Cisplatin; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Male; Middle Aged; Neoplasms; Protein Serine-Threonine Kinases; Treatment Outcome | 2011 |
Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Gemcitabine; Humans; Middle Aged; Neoplasms; Pyrazines | 2010 |
Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Genes, bcl-2; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Oligonucleotides, Antisense; Thionucleotides; Treatment Outcome | 2011 |
A dose escalation trial of biweekly docetaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2010 |
A phase I study of topotecan and gemcitabine in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topotecan; Treatment Outcome | 2011 |
Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Docetaxel; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Michigan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; New Jersey; Perfusion Imaging; Piperazines; Pyrimidines; Taxoids; Time Factors; Treatment Outcome | 2012 |
Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infant; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; Young Adult | 2011 |
Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Disease Progression; Female; Fever; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Neutropenia; Patient Dropouts; Pemetrexed; Pyrimidines; Renal Insufficiency; Severity of Illness Index; Young Adult | 2011 |
A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intravenous; Male; Mammalian orthoreovirus 3; Maximum Tolerated Dose; Middle Aged; Neoplasms; Oncolytic Virotherapy | 2011 |
Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Neoplasms; Pyrazines | 2011 |
Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Endostatins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Recombinant Proteins; Survival Rate; Taxoids; Treatment Outcome | 2010 |
The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C.
Topics: Alleles; Antimetabolites, Antineoplastic; Cross-Over Studies; Cytidine Deaminase; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Genotype; Humans; Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Time Factors | 2011 |
A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Male; Middle Aged; Neoplasms; Panobinostat; Treatment Outcome | 2011 |
Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Metabolic Clearance Rate; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Treatment Outcome | 2012 |
Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Deoxyuridine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Prodrugs; Quinazolines; Treatment Outcome; Young Adult | 2011 |
Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Hypertension; Indoles; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Niacinamide; Oligonucleotides; Quinazolines; Treatment Outcome; Venous Thrombosis; Vomiting; Young Adult | 2011 |
A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Piperidines; Pyridines | 2011 |
Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Pyrazines; Treatment Outcome; Young Adult | 2012 |
Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cell Cycle Proteins; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Gemcitabine; Glycine; Humans; Lymphopenia; Male; Middle Aged; Neoplasms; Neutropenia; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinase; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Signal Transduction; Sulfones; Survival Analysis; Treatment Outcome | 2012 |
A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2012 |
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Panitumumab; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, IGF Type 1; Sorafenib | 2012 |
Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Depsipeptides; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2012 |
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyridines; Ribonucleoside Diphosphate Reductase; Thiosemicarbazones; Thrombocytopenia | 2013 |
Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sunitinib | 2012 |
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Gemcitabine; Humans; Indazoles; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrimidines; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cell Hypoxia; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neoplasms; Nitrogen Mustard Compounds; Prodrugs; Taxoids | 2012 |
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Dasatinib; Demography; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Interleukin-8; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Neoplastic Cells, Circulating; Pyrimidines; Thiazoles; Young Adult | 2013 |
Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Demography; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms | 2013 |
A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel | 2013 |
Irinotecan and gemcitabine in patients with solid tumors: phase I trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Maximum Tolerated Dose; Nausea; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Vomiting | 2002 |
Pilot study of gemcitabine (10 mg/m(2) per min) and cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Pilot Projects | 2002 |
A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Area Under Curve; Biotransformation; Chromatography, High Pressure Liquid; Deoxycytidine; Docetaxel; Drug Interactions; Female; Gemcitabine; Half-Life; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2002 |
Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Reference Values; Survival Analysis; Treatment Outcome | 2002 |
Phase I trial of gemcitabine, administered as a standard and constant dose-rate infusion, in combination with paclitaxel in patients with advanced solid tumors (LOA-2).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Urologic Neoplasms | 2002 |
Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Gemcitabine; Humans; Liposomes; Male; Middle Aged; Neoplasms; Neutropenia; Stomatitis; Treatment Outcome | 2002 |
Phase I study of rubitecan and gemcitabine in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Risk Assessment; Survival Analysis; Treatment Outcome | 2002 |
Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; California; Chemical and Drug Induced Liver Injury; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Gemcitabine; Humans; Hydroxyurea; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2002 |
Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymphoma; Male; Middle Aged; Neoplasms; Patients; Uracil | 2002 |
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin | 2003 |
A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Darbepoetin alfa; Deoxycytidine; Docetaxel; Erythropoietin; Fatigue; Female; Gemcitabine; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Paclitaxel; Pilot Projects; Taxoids; Treatment Outcome | 2003 |
Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cell Survival; Cohort Studies; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Urothelium | 2003 |
Phase I trial of gemcitabine and paclitaxel in advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Prospective Studies; Thrombocytopenia; Treatment Outcome | 2003 |
Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over Studies; Cytoprotection; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms | 2003 |
Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Vinblastine; Vinorelbine | 2003 |
Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome | 2003 |
Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasms | 2003 |
A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Electrolytes; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Maximum Tolerated Dose; Middle Aged; Mouth Mucosa; Neoplasms; Quinolones; Time Factors | 2003 |
A phase I study of gemcitabine and docetaxel for advanced stage solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Patient Selection; Taxoids | 2003 |
A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Floxuridine; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Ribonucleotide Reductases; Thrombocytopenia | 2003 |
A phase I human trial of mitoguazone and gemcitabine sequential bi-weekly treatment of cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Mitoguazone; Neoplasms | 2003 |
Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2003 |
A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
Topics: Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Antimetabolites, Antineoplastic; Area Under Curve; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gemcitabine; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Models, Chemical; Neoplasms; Protein Prenylation; Quinolones; ras Proteins; Time Factors; Treatment Outcome | 2003 |
Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Drug Interactions; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Quinazolines; Treatment Outcome | 2004 |
A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasms; Organoplatinum Compounds | 2004 |
A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Methemoglobinemia; Middle Aged; Neoplasms; Pyridines; Ribonucleotide Reductases; Thiosemicarbazones | 2004 |
Gemcitabine in patients with solid tumors and renal impairment: a pharmacokinetic phase I study.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Floxuridine; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Renal Insufficiency | 2004 |
Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Child, Preschool; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Half-Life; Humans; Male; Maximum Tolerated Dose; Neoplasms | 2004 |
A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung; Male; Middle Aged; Neoplasms; Prospective Studies; Pulmonary Diffusing Capacity | 2004 |
Phase I trial of topotecan in combination with gemcitabine in refractory solid tumor patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prospective Studies; Topotecan; Treatment Outcome | 2004 |
Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms | 2005 |
A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Pemetrexed | 2005 |
Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.
Topics: Aged; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Cytidine Deaminase; Deoxycytidine; DNA Mutational Analysis; DNA, Neoplasm; Exanthema; Fatigue; Floxuridine; Gemcitabine; Genotype; Humans; Japan; Male; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Single Nucleotide; Stomatitis; Thrombocytopenia; Treatment Outcome | 2005 |
Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolones | 2005 |
Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Synergism; Female; Folic Acid Antagonists; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Kidney; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrimidines; Salvage Therapy; Treatment Outcome | 2005 |
Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Endometrial Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasms; Ovarian Neoplasms | 2006 |
A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2006 |
Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2006 |
Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Time Factors | 2006 |
A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Interactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Oligopeptides; Thrombospondin 1 | 2006 |
Pharmacokinetic evaluation of gemcitabine and 2',2'-difluorodeoxycytidine-5'-triphosphate after prolonged infusion in patients affected by different solid tumors.
Topics: Adult; Aged; Cytidine Triphosphate; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Survival Analysis; Time Factors; Treatment Outcome | 2006 |
Topoisomerase I, II alpha and II beta mRNA expression in peripheral blood mononuclear cells of patients with solid tumor: preliminary results.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Deoxycytidine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Administration Schedule; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Leukocytes, Mononuclear; Middle Aged; Neoplasms; RNA, Messenger; Time Factors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2006 |
Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic origin.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Child; Child, Preschool; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasms; Prospective Studies; Sample Size | 2006 |
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2006 |
A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Ribonucleoside Diphosphate Reductase; RNA, Messenger | 2007 |
Coadministration of oxaliplatin does not influence the pharmacokinetics of gemcitabine.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Deoxycytidine; Drug Interactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Platinum; Treatment Outcome | 2006 |
Phase I study of bryostatin 1 and gemcitabine.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bryostatins; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2006 |
A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Treatment Outcome | 2007 |
Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms | 2007 |
A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Small Cell; Cholangiocarcinoma; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; Female; Gastrointestinal Hemorrhage; Gemcitabine; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasms | 2007 |
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Epothilones; Female; Gemcitabine; Humans; Kidney Neoplasms; Leukopenia; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Uterine Neoplasms; Water-Electrolyte Imbalance | 2007 |
A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasms; Tegafur; Uracil | 2007 |
Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Neoplasms | 2007 |
A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Patient Compliance; Stomach Neoplasms; Taxoids; Treatment Outcome | 2006 |
A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Polyethylene Glycols; Survival Rate | 2007 |
A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines | 2007 |
A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pemetrexed | 2006 |
Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; CD146 Antigen; Cisplatin; Deoxycytidine; Endothelium, Vascular; Female; Gemcitabine; Glycoproteins; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Peptides; Prognosis; Protein Kinase C; Protein Kinase C beta; RNA, Messenger; Survival Rate | 2007 |
A dose escalation study of biweekly oral vinorelbine and gemcitabine in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Flavonoids; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Piperidines; Taxoids; Treatment Outcome | 2007 |
Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Piperazines; Pyrimidines; Treatment Outcome | 2007 |
Dose escalating study of biweekly gemcitabine and carboplatin in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Neoplasms; Patient Selection | 2007 |
Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Neoplasms; Taxoids; Transplantation, Autologous | 2007 |
Randomized crossover study evaluating the effect of gemcitabine infusion dose rate: evidence of auto-induction of gemcitabine accumulation.
Topics: Antimetabolites, Antineoplastic; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Neoplasms | 2007 |
A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Epothilones; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2008 |
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Deoxycytidine; Dioxoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2008 |
Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I study.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms | 1994 |
Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Fever; Gemcitabine; Humans; Male; Middle Aged; Neoplasms | 1994 |
[An early phase II study of gemcitabine hydrochloride (LY 188011). Gemcitabine Cooperative Study Group for Early Phase II].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Stomach Neoplasms; Uterine Cervical Neoplasms | 1996 |
Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusion Pumps; Infusions, Intravenous; Male; Middle Aged; Neoplasms | 1997 |
A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Blood Cell Count; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Pancreatic Neoplasms; Survival Analysis | 1997 |
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel | 1998 |
Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neoplasms; Treatment Outcome | 1998 |
Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Deoxycytidine; DNA Adducts; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukocytes; Linear Models; Male; Middle Aged; Neoplasms; Statistics, Nonparametric; Treatment Outcome | 1999 |
Gemcitabine and UFT plus oral calcium folinate: phase I study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; DNA, Neoplasm; Drug Administration Routes; Female; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasms; Ribonucleotide Reductases; Tegafur; Treatment Outcome; Uracil | 1999 |
Leucovorin, 5-fluorouracil, and gemcitabine: a phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasms; Time Factors; Treatment Outcome | 1999 |
A phase I trial of MTA and gemcitabine in patients with locally advanced or metastatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Enzyme Inhibitors; Female; Folic Acid Antagonists; Gallbladder Neoplasms; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Pemetrexed | 1999 |
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia; Treatment Outcome | 2000 |
A phase I trial of gemcitabine and infusional 5-fluorouracil (5-FU) in patients with refractory solid tumors: Louisiana Oncology Associates protocol no. 1 (LOA-1).
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms | 2000 |
A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Platelet Count; Vinblastine; Vinorelbine | 2000 |
Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy | 2000 |
Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Male; Middle Aged; Neoplasms; Pemetrexed; Tumor Cells, Cultured | 2000 |
A phase I trial of docetaxel and gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.
Topics: Aged; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Bilirubin; Creatinine; Deoxycytidine; Female; Gemcitabine; Humans; Liver Diseases; Liver Function Tests; Male; Middle Aged; Models, Biological; Neoplasms; Renal Insufficiency | 2000 |
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Differentiation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Quinolines; Thrombocytopenia; Vomiting | 2000 |
[Decline in the need for blood transfusions in cancer patients due to the use of epoietin alfa during cisplatin based chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Gemcitabine; Hematinics; Humans; Male; Middle Aged; Neoplasms; Recombinant Proteins; Treatment Outcome | 2001 |
Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 2001 |
A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Thrombocytopenia; Topotecan; Treatment Outcome | 2001 |
Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2001 |
Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms | 2001 |
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome | 2001 |
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Neutropenia; Pancreatic Neoplasms; Stomatitis; Treatment Outcome | 2002 |
Combination chemotherapy of carboplatin and gemcitabine against solid tumors: a phase I trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Hematologic Diseases; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Treatment Outcome | 2001 |
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Indoles; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Pyrroles; Thromboembolism; Treatment Outcome | 2002 |
Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasms | 1992 |
Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Evaluation; Gemcitabine; Humans; Leukocytes, Mononuclear; Neoplasms | 1991 |
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Evaluation; Gemcitabine; Half-Life; Humans; Metabolic Clearance Rate; Middle Aged; Neoplasms | 1991 |
243 other study(ies) available for gemcitabine and Benign Neoplasms
| Article | Year |
|---|---|
Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Division; Deoxycytidine; DNA Damage; Gemcitabine; Humans; Multidrug Resistance-Associated Proteins; Neoplasms; Phosphorylation; Tumor Cells, Cultured | 2003 |
Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Dose-Response Relationship, Drug; Indoles; Mice; Models, Molecular; Molecular Structure; Neoplasms; Oxindoles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Stereoisomerism; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2006 |
Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Neoplasms; Pancreas; Pancreatic Neoplasms; Structure-Activity Relationship | 2013 |
Hybrids of phenylsulfonylfuroxan and coumarin as potent antitumor agents.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinogenesis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Coumarins; Drug Combinations; Drug Screening Assays, Antitumor; Female; HeLa Cells; Human Umbilical Vein Endothelial Cells; Humans; Inhibitory Concentration 50; MAP Kinase Kinase 1; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase 3; Neoplasms; Nitric Oxide; Oxadiazoles; Signal Transduction | 2014 |
Synthesis, in vitro, and in vivo evaluation of novel functionalized quaternary ammonium curcuminoids as potential anti-cancer agents.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Cell Movement; Curcumin; Female; Humans; Mice; Mice, Nude; Neoplasms; Quaternary Ammonium Compounds; Transplantation, Heterologous | 2015 |
Synthesis and Cytostatic and Antiviral Profiling of Thieno-Fused 7-Deazapurine Ribonucleosides.
Topics: Antineoplastic Agents; Antiviral Agents; Cell Line, Tumor; Hepacivirus; Hepatitis C; Humans; Neoplasms; Purines; Ribonucleosides | 2017 |
In vitro and in vivo pharmacokinetic and pharmacodynamic study of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.
Topics: Animals; Antineoplastic Agents; Blood Proteins; Cell Line, Tumor; Cytochrome P-450 Enzyme System; Deuterium; Diketopiperazines; Female; Half-Life; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Inbred BALB C; Microsomes, Liver; Neoplasms; Protein Binding; Rats; Rats, Wistar; Tissue Distribution | 2018 |
DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.
Topics: Aminoglycosides; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Drug Synergism; Enzyme Inhibitors; Humans; N-Acetylglucosaminyltransferases; Neoplasms; Paclitaxel; Snail Family Transcription Factors; Structure-Activity Relationship | 2020 |
Design, synthesis and biological evaluation of second-generation benzoylpiperidine derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Enzyme Inhibitors; Humans; Mice; Molecular Dynamics Simulation; Monoacylglycerol Lipases; Neoplasms; Piperidines | 2021 |
Discovery and optimization of betulinic acid derivatives as novel potent CD73 inhibitors.
Topics: 5'-Nucleotidase; Adenosine; Betulinic Acid; Humans; Immunotherapy; Neoplasms; Pentacyclic Triterpenes | 2022 |
N-trimethyl chitosan coated nano-complexes enhance the oral bioavailability and chemotherapeutic effects of gemcitabine.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chitosan; Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; Male; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Polylactic Acid-Polyglycolic Acid Copolymer; Rats, Sprague-Dawley; Vitamin E | 2021 |
Redox-responsive self-assembled polymeric nanoprodrug for delivery of gemcitabine in B-cell lymphoma therapy.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Lymphoma; Lymphoma, B-Cell; Mice; Micelles; Nanoparticles; Neoplasms; Oxidation-Reduction; Polymers; Prodrugs; Tumor Microenvironment | 2022 |
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Nivolumab | 2022 |
Acute generalized exanthematous pustulosis caused by gemcitabine after nivolumab in metastatic lung adenocarcinoma followed by a dramatic tumor response: A case report.
Topics: Acute Generalized Exanthematous Pustulosis; Adenocarcinoma of Lung; Aged; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasms; Nivolumab | 2022 |
GITR Antibodies in Cancer: Not Ready for Prime Time.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Glucocorticoid-Induced TNFR-Related Protein; Humans; Neoplasms; Nivolumab; T-Lymphocytes, Regulatory | 2022 |
Promotion of tumor progression induced by continuous low-dose administration of antineoplastic agent gemcitabine or gemcitabine combined with cisplatin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Cell Line, Tumor; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasms | 2022 |
Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies.
Topics: Deoxycytidine; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Neoplasms; Retrospective Studies | 2022 |
Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination.
Topics: B7-H1 Antigen; Cancer Vaccines; Dendritic Cells; Gemcitabine; Hepatitis A Virus Cellular Receptor 2; Humans; Immune Checkpoint Inhibitors; Neoplasms; Vaccination | 2022 |
Plasma membrane lipid bilayer is druggable: Selective delivery of gemcitabine-squalene nano-medicine to cancer cells.
Topics: Cell Membrane; Gemcitabine; Lipid Bilayers; Neoplasms; Prodrugs; Squalene | 2023 |
Macrophage Membrane-Coated Nano-Gemcitabine Promotes Lymphocyte Infiltration and Synergizes AntiPD-L1 to Restore the Tumoricidal Function.
Topics: B7-H1 Antigen; CD8-Positive T-Lymphocytes; Gemcitabine; Humans; Immunotherapy; Interferon-gamma; Macrophages; Nanostructures; Neoplasms; Tumor Microenvironment | 2023 |
Gold Nanoparticles Synthesized by an Aqueous Extract of
Topics: Chlorophyta; Gemcitabine; Gold; Green Chemistry Technology; Humans; Metal Nanoparticles; Neoplasms; Plant Extracts; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2022 |
Chemotherapy-Associated Thrombotic Microangiopathy.
Topics: Antineoplastic Agents; Gemcitabine; Humans; Neoplasms; Proteasome Inhibitors; Thrombotic Microangiopathies | 2023 |
ROS-Triggered Self-Assembled Nanoparticles Based on a Chemo-Sonodynamic Combinational Therapy Strategy for the Noninvasive Elimination of Hypoxic Tumors.
Topics: Animals; Combined Modality Therapy; Drug Delivery Systems; Gemcitabine; HeLa Cells; Humans; Intracellular Space; Mice; Nanoparticles; Neoplasms; Reactive Oxygen Species; Tumor Hypoxia; Tumor Microenvironment | 2023 |
Triple-Combination Immunogenic Nanovesicles Reshape the Tumor Microenvironment to Potentiate Chemo-Immunotherapy in Preclinical Cancer Models.
Topics: Animals; B7-H1 Antigen; CD8-Positive T-Lymphocytes; Gemcitabine; Humans; Immunotherapy; Mice; Neoplasms; Tumor Microenvironment | 2023 |
Radiation Therapies in Cancer.
Topics: Gemcitabine; Humans; Immunotherapy; Mitomycin; Neoplasms; Nimorazole | 2023 |
DCK confers sensitivity of DCTD-positive cancer cells to oxidized methylcytidines.
Topics: Gemcitabine; Humans; Neoplasms | 2023 |
Multi-stimuli-responsive chitosan-functionalized magnetite/poly(ε-caprolactone) nanoparticles as theranostic platforms for combined tumor magnetic resonance imaging and chemotherapy.
Topics: Animals; Chitosan; Ferrosoferric Oxide; Gemcitabine; Humans; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice; Mice, SCID; Nanoparticles; Neoplasms; Precision Medicine | 2023 |
Multitargeting Prodrugs that Release Oxaliplatin, Doxorubicin and Gemcitabine are Potent Inhibitors of Tumor Growth and Effective Inducers of Immunogenic Cell Death.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Doxorubicin; Gemcitabine; Humans; Immunogenic Cell Death; Mice; Neoplasms; Oxaliplatin; Prodrugs | 2023 |
Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients.
Topics: Anemia; Biomarkers; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Neoplasms | 2023 |
Oral Delivery of Gemcitabine-Loaded Glycocholic Acid-Modified Micelles for Cancer Therapy.
Topics: Administration, Oral; Animals; Gemcitabine; Glycocholic Acid; Humans; Mice; Micelles; Neoplasms | 2023 |
Topics: Gemcitabine; Humans; Muscles; Neoplasms | 2023 |
Sample preparation strategies for high-throughput mass spectrometry imaging of primary tumor organoids.
Topics: Centrifugation; Collagen; Deoxycytidine; Drug Combinations; Extracellular Matrix; Fluorouracil; Gemcitabine; Humans; Laminin; Neoplasms; Organoids; Proteoglycans; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Array Analysis; Workflow | 2020 |
Highly Porous Hybrid Metal-Organic Nanoparticles Loaded with Gemcitabine Monophosphate: a Multimodal Approach to Improve Chemo- and Radiotherapy.
Topics: Antineoplastic Agents; Deoxycytidine; DNA Repair; Gemcitabine; HeLa Cells; Humans; Metal-Organic Frameworks; Nanoparticles; Neoplasms; Particle Size; Porosity; Surface Properties | 2020 |
Exosomes as a Surrogate Marker for Autophagy in Peripheral Blood, Correlative Data from Phase I Study of Chloroquine in Combination with Carboplatin/Gemcitabine in Advanced Solid Tumors.
Topics: Antimalarials; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Biomarkers; Carboplatin; Chloroquine; Deoxycytidine; Drug Therapy, Combination; Exosomes; Gemcitabine; Humans; Neoplasms; Tumor Cells, Cultured | 2019 |
Liquid Formulation of Gemcitabine Increases Venous Pain in Patients With Cancer: A Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Compounding; Female; Freeze Drying; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Pain; Retrospective Studies; Risk Factors | 2020 |
Assessment of Anti-Tumor potential and safety of application of Glutathione stabilized Gold Nanoparticles conjugated with Chemotherapeutics.
Topics: Chromatography, High Pressure Liquid; Cytarabine; Deoxycytidine; Doxorubicin; Gemcitabine; Glutathione; Gold; Humans; MCF-7 Cells; Metal Nanoparticles; Microscopy, Electron, Transmission; Neoplasms; Osteoblasts; Telomerase | 2020 |
Leveraging TCGA gene expression data to build predictive models for cancer drug response.
Topics: Antineoplastic Agents; Area Under Curve; Cluster Analysis; Databases, Genetic; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Machine Learning; Neoplasms; ROC Curve | 2020 |
Poly(anhydride-ester) gemcitabine: Synthesis and particle engineering of a high payload hydrolysable polymeric drug for cancer therapy.
Topics: Anhydrides; Animals; Deoxycytidine; Drug Delivery Systems; Esters; Gemcitabine; Humans; Mice; Neoplasms; Pharmaceutical Preparations; Polymers | 2021 |
Chk1 inhibition induces a DNA damage bystander effect in cocultured tumour cells.
Topics: Ataxia Telangiectasia Mutated Proteins; Bystander Effect; Camptothecin; Cell Line, Tumor; Checkpoint Kinase 1; Coculture Techniques; Deoxycytidine; DNA; DNA Damage; DNA-Activated Protein Kinase; Gemcitabine; Histones; HT29 Cells; Humans; Jurkat Cells; Neoplasms; Protein Kinase Inhibitors; Signal Transduction | 2021 |
An Amphiphilic PEGylated Peptide Dendron-Gemcitabine Prodrug-Based Nanoagent for Cancer Therapy.
Topics: Animals; Cell Line, Tumor; Dendrimers; Deoxycytidine; Gemcitabine; Nanoparticles; Neoplasms; Peptides; Polyethylene Glycols; Prodrugs | 2021 |
Quantifying cell cycle-dependent drug sensitivities in cancer using a high throughput synchronisation and screening approach.
Topics: Cell Culture Techniques; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; HeLa Cells; High-Throughput Screening Assays; Humans; MCF-7 Cells; Neoplasms; Nocodazole; Piperazines; Pyridines; Small Molecule Libraries; Time Factors; Tubulin Modulators | 2021 |
New In Vitro-In Silico Approach for the Prediction of In Vivo Performance of Drug Combinations.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Computer Simulation; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Models, Biological; Neoplasms | 2021 |
Hippo pathway mediates resistance to cytotoxic drugs.
Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Line; Cytotoxins; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Hippo Signaling Pathway; Humans; Mice; Neoplasms; Phosphoproteins; Protein Serine-Threonine Kinases; Signal Transduction; Transcription Factors; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2017 |
Tumor regression is mediated via the induction of HER263-71- specific CD8+ CTL activity in a 4T1.2/HER2 tumor model: no involvement of CD80 in tumor control.
Topics: Animals; Antigens, Neoplasm; Biomarkers; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Immunoglobulin G; Interferon-gamma; Mice; Mice, Knockout; Neoplasms; Receptor, ErbB-2; T-Cell Antigen Receptor Specificity; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic; Th1 Cells; Tumor Burden | 2017 |
Conjugation of squalene to gemcitabine as unique approach exploiting endogenous lipoproteins for drug delivery.
Topics: A549 Cells; Animals; Calorimetry; Cell Line; Cell Line, Tumor; Cholesterol; Deoxycytidine; Drug Delivery Systems; Fluorescence Resonance Energy Transfer; Gemcitabine; Humans; Ligands; Lipoproteins; Liposomes; MCF-7 Cells; Nanoparticles; Neoplasms; Rats; Receptors, LDL; Squalene | 2017 |
Ternary cocktail nanoparticles for sequential chemo-photodynamic therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Carriers; Gemcitabine; Humans; Nanoparticles; Neoplasms; Photochemotherapy; Taxoids | 2017 |
Functional Characterization of VEGF- and FGF-induced Tumor Blood Vessel Models in Human Cancer Xenografts.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Fibroblast Growth Factors; Gemcitabine; Humans; Immunohistochemistry; Mice; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2017 |
Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytarabine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Infusions, Intravenous; Isoflurophate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neoplasms; Paclitaxel; Xenograft Model Antitumor Assays | 2018 |
Gemcitabine-loaded gold nanospheres mediated by albumin for enhanced anti-tumor activity combining with CT imaging.
Topics: A549 Cells; Animals; Antimetabolites, Antineoplastic; Cattle; Cell Survival; Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; Gold; Humans; Hydrogen-Ion Concentration; Nanospheres; Neoplasms; Serum Albumin, Bovine; Tomography, X-Ray Computed | 2018 |
Multifunctional Tumor-Targeting Cathepsin B-Sensitive Gemcitabine Prodrug Covalently Targets Albumin in Situ and Improves Cancer Therapy.
Topics: Animals; Cathepsin B; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Male; Mice; Neoplasms; Prodrugs; Rats, Sprague-Dawley; Serum Albumin | 2018 |
Real-Time Monitoring of Cancer Cells in Live Mouse Bone Marrow.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Marrow; Cell Movement; Cell Survival; Cell Tracking; Deoxycytidine; Flow Cytometry; Gemcitabine; Humans; Immune Tolerance; Intravital Microscopy; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Mice, Transgenic; Microscopy, Fluorescence, Multiphoton; Models, Animal; Neoplasms; Statistics, Nonparametric; Tumor Microenvironment | 2018 |
Carrier-free Janus nano-prodrug based on camptothecin and gemcitabine: Reduction-triggered drug release and synergistic in vitro antiproliferative effect in multiple cancer cells.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Janus Kinases; Nanoparticles; Neoplasms; Oxidation-Reduction; Prodrugs | 2018 |
Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; France; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Pharmacovigilance; Retrospective Studies; Thrombotic Microangiopathies | 2019 |
Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy.
Topics: Algorithms; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Computational Biology; Databases, Factual; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Genome, Human; Humans; Machine Learning; Neoplasms; Ovarian Neoplasms; Precision Medicine; Predictive Value of Tests; Support Vector Machine; Transcriptome | 2018 |
Oxaliplatin regulates myeloid-derived suppressor cell-mediated immunosuppression via downregulation of nuclear factor-κB signaling.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Immune Tolerance; Mice, Inbred BALB C; Myeloid-Derived Suppressor Cells; Neoplasms; NF-kappa B; Oxaliplatin; T-Lymphocytes | 2019 |
Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?
Topics: Biomarkers; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Neoplasms | 2019 |
A novel low molecular weight nanocomposite hydrogel formulation for intra-tumoural delivery of anti-cancer drugs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Liberation; Gemcitabine; Humans; Hyaluronic Acid; Hydrogels; Injections; Molecular Weight; Nanocomposites; Neoplasms; Polyglutamic Acid; Rheology | 2019 |
Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.
Topics: Animals; Arginine; Argininosuccinate Synthase; Cell Line, Tumor; Cell Membrane; Deoxycytidine; Disease Models, Animal; Docetaxel; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Models, Biological; Neoplasms; Protein Binding; Protein Transport; Proto-Oncogene Proteins c-myc; Xenograft Model Antitumor Assays | 2019 |
Polygemcitabine nanogels with accelerated drug activation for cancer therapy.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Deoxycytidine; Gels; Gemcitabine; Humans; Mice, Nude; Nanoparticles; Neoplasms; Polymers; Prodrugs; Xenograft Model Antitumor Assays | 2019 |
Dual-Responsive Micelles with Aggregation-Induced Emission Feature and Two-Photon Aborsption for Accurate Drug Delivery and Bioimaging.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Female; Fluorescent Dyes; Gemcitabine; Humans; Hydrogen-Ion Concentration; Mice; Mice, Inbred BALB C; Micelles; Neoplasms; Optical Imaging; Polymers | 2019 |
Gemcitabine-coumarin-biotin conjugates: a target specific theranostic anticancer prodrug.
Topics: Antineoplastic Agents; Biotin; Cell Line, Tumor; Cell Survival; Coumarins; Deoxycytidine; Drug Delivery Systems; Fluorescent Dyes; Gemcitabine; Humans; Neoplasms; Prodrugs; Sulfhydryl Compounds | 2013 |
Gemcitabine-loaded smart carbon nanotubes for effective targeting to cancer cells.
Topics: Cell Line, Tumor; Chemistry, Pharmaceutical; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Folic Acid; Gemcitabine; Humans; MCF-7 Cells; Nanotubes, Carbon; Neoplasms; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2013 |
[Optimizing good use and costs of anticancer drugs: A French inter regional study of the Observatory of Cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cost Savings; Deoxycytidine; Drug Costs; France; Gemcitabine; Humans; Neoplasms; Quality Improvement | 2013 |
[Possibilities of epigenetic anti-tumor therapy in in-vitro models].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butyric Acid; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Epigenesis, Genetic; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Neoplasms; Radiotherapy, Adjuvant; Salts; Sodium; Time Factors; Valproic Acid | 2012 |
Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells.
Topics: Adenocarcinoma; Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasms; Neoplastic Stem Cells; Neovascularization, Pathologic; Ovarian Neoplasms; Pancreatic Neoplasms; Random Allocation; Thrombospondin 1; Xenograft Model Antitumor Assays | 2013 |
An insight into potential of nanoparticles-assisted chemotherapy of cancer using gemcitabine and its fatty acid prodrug:a comparative study.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Fatty Acids; Female; Gemcitabine; Humans; Male; Mice; Nanoparticles; Neoplasms; Prodrugs; Rats; Rats, Wistar | 2013 |
Functionalized magnetic nanoparticles as vehicles for the delivery of the antitumor drug gemcitabine to tumor cells. Physicochemical in vitro evaluation.
Topics: Acrylic Resins; Adsorption; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chemical Phenomena; Deoxycytidine; Drug Delivery Systems; Electrophoresis; Folic Acid; Gemcitabine; Humans; Hydrogen-Ion Concentration; Magnetite Nanoparticles; Microscopy, Confocal; Neoplasms; Optical Imaging; Particle Size | 2013 |
Polymer prodrug nanoparticles based on naturally occurring isoprenoid for anticancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colloids; Deoxycytidine; Gemcitabine; Humans; Mice; Nanocapsules; Nanoparticles; Neoplasms; Polyethylene Glycols; Polymerization; Polymethacrylic Acids; Prodrugs; Squalene; Terpenes | 2013 |
Folate-based near-infrared fluorescent theranostic gemcitabine delivery.
Topics: Animals; Antimetabolites, Antineoplastic; Carbocyanines; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Fluorescent Dyes; Folic Acid; Gemcitabine; Humans; KB Cells; Mice; Neoplasms; Optical Imaging; Sulfhydryl Compounds | 2013 |
Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; DNA Replication; Gemcitabine; Humans; Mitosis; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles | 2013 |
Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India.
Topics: Camptothecin; Cost Savings; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Drugs, Generic; Gemcitabine; Humans; India; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Poverty; Taxoids | 2013 |
Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbolines; Cell Cycle Checkpoints; Checkpoint Kinase 1; Dacarbazine; Deoxycytidine; DNA Damage; Gemcitabine; HCT116 Cells; High-Throughput Nucleotide Sequencing; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Neoplasms, Experimental; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Cycle; Cell Proliferation; Chromatography, High Pressure Liquid; Computer Simulation; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Flow Cytometry; Gemcitabine; Half-Life; Humans; Hydroxyurea; Interleukin-2 Receptor alpha Subunit; Mice; Mice, Inbred NOD; Mice, SCID; Mutagenesis, Site-Directed; Mutation; Neoplasms; Protein Conformation; Ribonucleotide Reductases; Small Molecule Libraries; Structure-Activity Relationship; Surface Plasmon Resonance; Tandem Mass Spectrometry; Thiazoles | 2013 |
Gemcitabine-related thrombotic microangiopathy: a single-centre retrospective series.
Topics: Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Incidence; Male; Middle Aged; Neoplasms; Retrospective Studies; Thrombotic Microangiopathies | 2014 |
Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Doxorubicin; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Tumor Suppressor Protein p53 | 2014 |
Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine.
Topics: Adoptive Transfer; Animals; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Administration Schedule; Drug Synergism; Gemcitabine; Immunologic Memory; Lymphocyte Depletion; Lymphocytes, Tumor-Infiltrating; Melphalan; Mice; Myeloid Cells; Neoplasms; Recombinant Fusion Proteins; T-Lymphocytes, Regulatory | 2013 |
Multifunctional squalene-based prodrug nanoparticles for targeted cancer therapy.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Nanomedicine; Nanoparticles; Neoplasms; Prodrugs; Squalene; Tumor Cells, Cultured | 2014 |
CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzophenones; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Deoxycytidine; Female; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Mice, Mutant Strains; Microtubules; Neoplasms; Neovascularization, Pathologic; Tubulin; Tumor Burden; Valine; Xenograft Model Antitumor Assays | 2014 |
Genetic factors associated with gemcitabine pharmacokinetics, disposition, and toxicity.
Topics: 5-Lipoxygenase-Activating Proteins; Antimetabolites, Antineoplastic; Asian People; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Gene-Environment Interaction; Genetic Markers; Genome-Wide Association Study; Genome, Human; Genotype; Humans; Models, Genetic; Neoplasms; Neutropenia; Polymorphism, Single Nucleotide; Signal Transduction | 2014 |
MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors.
Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Everolimus; Female; Gemcitabine; Humans; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-3; Receptor, IGF Type 1; Signal Transduction; Sirolimus; Taxoids; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.
Topics: 5'-Nucleotidase; Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; Female; Gemcitabine; Genotype; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Membrane Transport Proteins; Middle Aged; Neoplasms; Young Adult | 2014 |
Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cytostatic Agents; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Herb-Drug Interactions; Humans; Male; Mitoxantrone; Neoplasms; Plant Extracts; Plants, Medicinal; Taxoids; Viscum album | 2014 |
The combination of i-leader truncation and gemcitabine improves oncolytic adenovirus efficacy in an immunocompetent model.
Topics: Adenoviridae; Animals; Cell Line, Tumor; Cricetinae; Deoxycytidine; DNA Primers; Fluorescence; Gemcitabine; HEK293 Cells; Humans; Immunohistochemistry; Mesocricetus; Mice; Mutation, Missense; Neoplasms; Oncolytic Virotherapy; Protein Sorting Signals; Statistics, Nonparametric; Virus Release | 2014 |
Noninvasive quantification of solid tumor microstructure using VERDICT MRI.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Female; Gemcitabine; Humans; Mice; Models, Theoretical; Neoplasms | 2014 |
The synthesis of gemcitabine.
Topics: Carbohydrates; Deoxycytidine; Fluorine; Gemcitabine; Halogenation; Humans; Molecular Structure; Neoplasms; Stereoisomerism | 2014 |
Pneumocystis jirovecii pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis.
Topics: Aged; Antibiotic Prophylaxis; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Australia; Deoxycytidine; Female; Gemcitabine; Humans; Immunocompromised Host; Male; Middle Aged; Neoplasms; Pneumocystis carinii; Pneumonia, Pneumocystis | 2015 |
Multifunctional polymersomes for cytosolic delivery of gemcitabine and doxorubicin to cancer cells.
Topics: Acoustics; Calorimetry, Differential Scanning; Cell Line, Tumor; Cell Survival; Chromatography, Gel; Cytosol; Deoxycytidine; Doxorubicin; Drug Delivery Systems; Fluoresceins; Fluorescence; Gemcitabine; Humans; Hydrogen-Ion Concentration; Liposomes; Microscopy, Atomic Force; Microscopy, Confocal; Neoplasms; Oxidation-Reduction; Particle Size; Polymers; Reducing Agents; Spectrophotometry, Ultraviolet; Spheroids, Cellular; Ultrasonics | 2014 |
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Deoxycytidine; Drug Therapy, Combination; Female; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Mice; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Retinoblastoma Protein; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
In situ evaluation of gemcitabine-DNA interaction using a DNA-electrochemical biosensor.
Topics: Antimetabolites, Antineoplastic; Biosensing Techniques; Deoxycytidine; DNA; Electrochemical Techniques; Gemcitabine; Humans; Neoplasms; Nucleic Acid Conformation; Oxidation-Reduction | 2014 |
BRCA2 and RAD51 promote double-strand break formation and cell death in response to gemcitabine.
Topics: Antimetabolites, Antineoplastic; BRCA2 Protein; Cell Death; Cell Survival; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Replication; Gemcitabine; Humans; MCF-7 Cells; Neoplasms; Rad51 Recombinase | 2014 |
NKG2D-directed cytokine-activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cell Line, Tumor; Combined Modality Therapy; Cytokine-Induced Killer Cells; Cytotoxicity, Immunologic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; NK Cell Lectin-Like Receptor Subfamily K; Retrospective Studies | 2014 |
A novel cytidine analog, RX-3117, shows potent efficacy in xenograft models, even in tumors that are resistant to gemcitabine.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytidine; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; HCT116 Cells; HT29 Cells; Humans; Mice; Mice, Nude; Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Interactions of multitargeted kinase inhibitors and nucleoside drugs: Achilles heel of combination therapy?
Topics: Axitinib; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Nucleoside Transport Proteins; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2015 |
Screening analysis of ubiquitin ligases reveals G2E3 as a potential target for chemosensitizing cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; DNA Damage; DNA, Neoplasm; Drug Synergism; Gemcitabine; Gene Knockdown Techniques; HCT116 Cells; Histones; Humans; Molecular Targeted Therapy; Neoplasms; Phosphorylation; Protein Kinases; RNA, Small Interfering; Transfection; Ubiquitin-Protein Ligases | 2015 |
Safe and effective treatment of spontaneous neoplasms with interleukin 12 electro-chemo-gene therapy.
Topics: Animals; Antineoplastic Agents; Bleomycin; Deoxycytidine; Dogs; Electroporation; Female; Gemcitabine; Genetic Therapy; Interleukin-12; Male; Neoplasms; Plasmids; Treatment Outcome | 2015 |
Local iontophoretic administration of cytotoxic therapies to solid tumors.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Proliferation; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Dogs; Drug Delivery Systems; Equipment Design; Female; Gemcitabine; Humans; Injections, Intravenous; Iontophoresis; Mice, Inbred BALB C; Neoplasms; Skin; Survival Analysis; Tissue Distribution; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carboplatin; Cisplatin; Creatinine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lipocalin-2; Lipocalins; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Proto-Oncogene Proteins; Taxoids | 2015 |
Will targeting Chk1 have a role in the future of cancer therapy?
Topics: Checkpoint Kinase 1; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasms; Protein Kinases; Pyrazoles; Pyrimidines | 2015 |
Gemcitabine + platinum combination chemotherapy in patients with metastatic cancer who suffer from severe and irreversible hepatic impairment: a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Diseases; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Turkey | 2014 |
[Cytidine].
Topics: Antineoplastic Agents; Arabinonucleosides; Cytarabine; Cytidine; Deoxycytidine; Gemcitabine; Humans; Neoplasms | 2015 |
Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; MCF-7 Cells; MicroRNAs; Mutation; Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Ribonucleoside Diphosphate Reductase; Signal Transduction; Transfection; Tubulin | 2015 |
Estimation of Tumor Size Evolution Using Particle Filters.
Topics: Algorithms; Antimetabolites, Antineoplastic; Computer Simulation; Deoxycytidine; Diagnosis, Computer-Assisted; Gemcitabine; Half-Life; Humans; Models, Biological; Monte Carlo Method; Neoplasms; Tumor Burden | 2015 |
siRNA knockdown of mitochondrial thymidine kinase 2 (TK2) sensitizes human tumor cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Gene Knockdown Techniques; HeLa Cells; Humans; MCF-7 Cells; Mitochondria; Neoplasms; RNA, Small Interfering; Thymidine Kinase; Transfection | 2015 |
Tumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Deoxycytidine; Extracellular Fluid; Gemcitabine; Humans; Liposomes; Mice, SCID; Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2015 |
Chlorambucil gemcitabine conjugate nanomedicine for cancer therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Chlorambucil; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Nanoconjugates; Nanomedicine; Neoplasm Transplantation; Neoplasms | 2015 |
Cancer drugs can be four times more costly in some wealthy countries than in others.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Australia; Cost of Illness; Deoxycytidine; Developed Countries; Drug Industry; European Union; Gemcitabine; Humans; Neoplasms; New Zealand | 2015 |
Interstitial lung disease associated with gemcitabine: A Japanese retrospective cohort study.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Incidence; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplasms; Retrospective Studies; Risk Assessment; Risk Factors; Smoking | 2016 |
An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbazoles; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphoma, Mantle-Cell; Male; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Phthalimides; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2016 |
Self-assembled gemcitabine-gadolinium nanoparticles for magnetic resonance imaging and cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gadolinium; Gemcitabine; Humans; Injections, Intravenous; Magnetic Resonance Imaging; Mice, Nude; Nanoparticles; Neoplasms; Solutions | 2016 |
In vivo drug delivery of gemcitabine with PEGylated single-walled carbon nanotubes.
Topics: Animals; Antimetabolites, Antineoplastic; Calorimetry, Differential Scanning; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; Humans; Magnetic Resonance Spectroscopy; Mice; Mice, Nude; Microscopy, Electron, Transmission; Nanotubes, Carbon; Neoplasms; Polyethylene Glycols; Spectroscopy, Fourier Transform Infrared; Transplantation, Heterologous | 2016 |
Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in-vivo tumor imaging.
Topics: A549 Cells; Antineoplastic Agents; Cell Line; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Liberation; Gemcitabine; Gold; Humans; Nanocomposites; Nanoparticles; Neoplasms; Porosity; Serum Albumin, Bovine; Silicon Dioxide | 2016 |
The Role of Oxygen in Avascular Tumor Growth.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Models, Theoretical; Neoplasms; Oxygen; Oxygen Consumption; Tumor Cells, Cultured | 2016 |
Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy.
Topics: Animals; Cell Death; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Immunosuppression Therapy; Immunotherapy; Immunotherapy, Adoptive; Lipids; Mice, Inbred C57BL; Mice, Transgenic; Monocytes; Myeloid-Derived Suppressor Cells; Nanocapsules; Neoplasms; Pinocytosis; Spleen; T-Lymphocytes | 2016 |
CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.
Topics: Albumins; Animals; Antibodies; Antigen-Presenting Cells; Carcinoma, Pancreatic Ductal; CD40 Antigens; CD8-Positive T-Lymphocytes; Clone Cells; Deoxycytidine; Gemcitabine; Immunity, Innate; Interferon-gamma; Lymphocyte Subsets; Mice, Inbred C57BL; Mice, Knockout; Neoplasms; Paclitaxel; Pancreatic Neoplasms; T-Lymphocytes; Treatment Outcome; Tumor Microenvironment | 2016 |
Population Pharmacodynamic Model for Bayesian Prediction of Myelosuppression Profiles Based on Routine Clinical Data after Gemcitabine and Carboplatin Treatment.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bayes Theorem; Blood Cell Count; Carboplatin; Deoxycytidine; Erythrocytes; Female; Forecasting; Gemcitabine; Humans; Leukocytes; Male; Middle Aged; Models, Biological; Neoplasms; Retrospective Studies; Treatment Outcome | 2016 |
Gemcitabine treatment enhanced the anti-tumor effect of cytokine induced killer cells by depletion of CD4
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytokine-Induced Killer Cells; Cytokines; Cytotoxicity, Immunologic; Deoxycytidine; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Gemcitabine; Humans; Immunomodulation; Immunosuppressive Agents; Lymphocyte Depletion; Male; Mice; Neoplasms; Phenotype; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory | 2017 |
Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carboplatin; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; DNA Adducts; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Mass Spectrometry; Mice; Mutation; Neoplasms; Platinum; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2017 |
The Detection of Urinary Podocytes from Drug-Induced Glomerular Thrombotic Microangiopathy in Advanced Cancer Patients.
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Nephrotic Syndrome; Podocytes; Predictive Value of Tests; Protein Kinase Inhibitors; Retrospective Studies; Thrombotic Microangiopathies; Time Factors; Urinalysis; Urine | 2016 |
[Outpatient chemotherapy and oncology network : Onco Pays-de-la-Loire experiment].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Deoxycytidine; Female; Fluorouracil; France; Gemcitabine; Home Care Services; Humans; Male; Methotrexate; Middle Aged; Neoplasms; Trastuzumab | 2008 |
[Ethnic differences of genetic polymorphisms in cancer chemotherapy].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Polymorphism, Genetic | 2008 |
Enhancement of somatostatin-receptor-targeted (177)Lu-[DOTA(0)-Tyr(3)]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation.
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Neoplasms; Octreotide; Radiation-Sensitizing Agents; Radiopharmaceuticals; Receptors, Somatostatin; Up-Regulation | 2008 |
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Proliferation; Chemokine CXCL12; Deoxycytidine; Drug Therapy, Combination; Endothelial Cells; Female; Gemcitabine; Humans; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Paclitaxel; Stem Cells; Tumor Burden; Vascular Endothelial Growth Factor A | 2008 |
Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK).
Topics: Antimetabolites, Antineoplastic; Asian People; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Haplotypes; Humans; Japan; Neoplasms; Polymorphism, Single Nucleotide | 2008 |
Gemicitabine resistence and mesenchymal phenotype.
Topics: Antimetabolites, Antineoplastic; Cadherins; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Neoplasms; Phenotype | 2009 |
Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers.
Topics: Acrylamides; Animals; Antineoplastic Agents; Apoptosis; Biocompatible Materials; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gemcitabine; Male; Materials Testing; Molecular Structure; Neoplasm Transplantation; Neoplasms; Neovascularization, Physiologic; Polymers; Rats; Tissue Distribution | 2009 |
Development of a sensitive and selective LC-MS/MS method for simultaneous determination of gemcitabine and 2,2-difluoro-2-deoxyuridine in human plasma.
Topics: Antineoplastic Agents; Chromatography, Liquid; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Neoplasms; Sensitivity and Specificity; Tandem Mass Spectrometry | 2009 |
Effects of taxane-based chemotherapy on inhibin B and gonadotropins as biomarkers of spermatogenesis.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Deoxycytidine; Docetaxel; Fertility; Follicle Stimulating Hormone; Gemcitabine; Humans; Infertility, Male; Inhibins; Luteinizing Hormone; Male; Middle Aged; Neoplasms; Paclitaxel; Spermatogenesis; Taxoids; Testis; Ultrasonography; Young Adult | 2010 |
Call for clarity in the reporting of benefit associated with anticancer therapies.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Editorial Policies; Fluorouracil; Gemcitabine; Humans; Neoplasms; Pancreatic Neoplasms; Periodicals as Topic; Sensitivity and Specificity; Survival Analysis; Total Quality Management; Treatment Outcome | 2009 |
Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers.
Topics: Antimetabolites, Antineoplastic; Biomarkers; Cytarabine; Deoxycytidine; Ethnicity; Gemcitabine; Genetic Variation; Genome-Wide Association Study; Humans; Inhibitory Concentration 50; Linkage Disequilibrium; Neoplasms; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Polymorphism, Single Nucleotide; RNA, Messenger | 2009 |
High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Base Sequence; Cytidine Deaminase; Deoxycytidine; Female; Gemcitabine; Genetic Variation; Genotype; Humans; Male; Mutation; Neoplasms; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Reproducibility of Results; Transition Temperature | 2010 |
Toxicities of gemcitabine in patients with severe hepatic dysfunction.
Topics: Alanine Transaminase; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Bilirubin; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Leukocyte Count; Liver Diseases; Male; Neoplasms; Pancreatic Neoplasms; Platelet Count; Retrospective Studies | 2010 |
Conventional and complementary therapies: a tale of two research standards?
Topics: Acupuncture Therapy; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Complementary Therapies; Cyclohexanols; Deoxycytidine; Dietary Supplements; Evidence-Based Medicine; Gemcitabine; Hot Flashes; Humans; Neoplasms; Peptide Hydrolases; Risk Assessment; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing.
Topics: Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Genotype; Humans; Neoplasms; Patient Selection; Phenotype; Polymorphism, Genetic; Treatment Outcome | 2010 |
The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Glucose; Humans; Hypoglycemic Agents; Insulin; Metformin; Neoplasms; Pancreatic Neoplasms; Rosiglitazone; Thiazolidinediones | 2011 |
Immunoglobulin E-mediated severe anaphylaxis to paclitaxel.
Topics: Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Asthma; Cisplatin; Deoxycytidine; Drug Hypersensitivity; Dyspnea; Epitopes; Female; Gemcitabine; Humans; Hypersensitivity, Immediate; Hypotension; Immunoglobulin E; Middle Aged; Neoplasms; Paclitaxel; Pulmonary Atelectasis; Remission Induction; Skin Tests | 2010 |
In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents.
Topics: Antineoplastic Agents; Artemisinins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Flow Cytometry; Gemcitabine; Humans; Immunoblotting; Inhibitory Concentration 50; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Thalidomide | 2011 |
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Erlotinib Hydrochloride; Gemcitabine; Genetic Engineering; Humans; Lung Neoplasms; Mice; Mutation; Neoplasms; Proto-Oncogene Proteins p21(ras); Quinazolines; Survival Analysis; Vascular Endothelial Growth Factor A | 2010 |
Gemcitabine intercellular diffusion mediated by gap junctions: new implications for cancer therapy.
Topics: Antimetabolites, Antineoplastic; Antiviral Agents; Bystander Effect; Cell Line, Tumor; Deoxycytidine; Fluorescent Antibody Technique; Gap Junctions; Gemcitabine; Humans; Neoplasms | 2010 |
[Suppression of renin-angiotensin system and cancer therapy (discussion)].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Cimetidine; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Gemcitabine; Humans; Hypertension; Interferon-alpha; Life Style; Neoplasms; Oxonic Acid; Renin-Angiotensin System; Tegafur; Tetrazoles | 2010 |
Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Asian People; Computer Simulation; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Female; Floxuridine; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Polymorphism, Genetic; Polymorphism, Single Nucleotide | 2010 |
Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands.
Topics: Animals; Antibodies; Antibodies, Monoclonal; Antibody Specificity; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Heparin-binding EGF-like Growth Factor; Humans; Immunotherapy; Intercellular Signaling Peptides and Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Pancreatic Neoplasms; Transforming Growth Factor alpha | 2010 |
Finding the tumor copycat: approximating a human cancer.
Topics: Adenocarcinoma; Animals; Animals, Genetically Modified; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Division; Deoxycytidine; Disease Models, Animal; Gemcitabine; Mice; Neoplasms | 2010 |
Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arteries; Bevacizumab; Deoxycytidine; Gemcitabine; Humans; Ischemia; Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Thrombosis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Bayesian hierarchical changepoint methods in modeling the tumor growth profiles in xenograft experiments.
Topics: Animals; Bayes Theorem; Cell Proliferation; Confidence Intervals; Deoxycytidine; Gemcitabine; Mice; Models, Biological; Models, Statistical; Neoplasms; Thiophenes; Urea; Xenograft Model Antitumor Assays | 2011 |
Adenovirus-mediated Drosophila melanogaster deoxyribonucleoside kinase mutants combined with gemcitabine harbor a safe cancer treatment profile.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Cells, Cultured; Combined Modality Therapy; Deoxycytidine; Drosophila melanogaster; Female; Gemcitabine; Genes, Transgenic, Suicide; Genetic Therapy; Genetic Vectors; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mutant Proteins; Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Prohibitins; Xenograft Model Antitumor Assays | 2011 |
Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Hydrophobic and Hydrophilic Interactions; Magnetic Resonance Imaging; Magnetics; Magnetite Nanoparticles; Mice; Nanocomposites; Nanomedicine; Neoplasms; Prodrugs; Squalene; Xenograft Model Antitumor Assays | 2011 |
Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Genotype; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasms; Polymorphism, Genetic; White People | 2011 |
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Disease Progression; Drug Synergism; Female; Gemcitabine; Genes, p53; Humans; Mice; Mice, Nude; Mutation; Neoplasms; Nuclear Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Biphenyl Compounds; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Nitrophenols; Piperazines; Protein Binding; Proto-Oncogene Proteins c-bcl-2; RNA Interference; Sulfonamides; Ubiquitin Thiolesterase; Xenograft Model Antitumor Assays | 2011 |
Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Cancer Vaccines; CD4-Positive T-Lymphocytes; Deoxycytidine; Female; Gemcitabine; Humans; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Neoplasms; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory | 2011 |
Gene set analysis of purine and pyrimidine antimetabolites cancer therapies.
Topics: Antimetabolites; Antineoplastic Agents; Area Under Curve; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Genes, Neoplasm; Humans; Neoplasms; Phenotype; Purines; Pyrimidines; Reproducibility of Results; Thioguanine | 2011 |
EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Epidermal Growth Factor; ErbB Receptors; Gemcitabine; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Nanoparticles; Neoplasms; Ovalbumin; Tumor Burden | 2012 |
The relationship between treatment time of gemcitabine and development of hematologic toxicity in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Circadian Rhythm; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukocyte Count; Male; Middle Aged; Neoplasms; Odds Ratio; Retrospective Studies | 2011 |
Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells.
Topics: Base Composition; Base Sequence; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; DNA Methylation; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; MicroRNAs; Molecular Sequence Data; Neoplasms; Promoter Regions, Genetic; Protein Binding; RNA, Messenger | 2011 |
Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Blood Vessels; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Endothelial Cells; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasms; Neovascularization, Pathologic; Prodrugs; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
[Safety profiles of gemcitabine hydrochloride(GEMZAR®)in Japanese clinical studies].
Topics: Antimetabolites, Antineoplastic; Cell Proliferation; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Japan; Lung Diseases, Interstitial; Myeloid Cells; Neoplasms | 2011 |
High-pressure intrapleural chemotherapy: feasibility in the pig model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Neoplasms; Pleural Neoplasms; Pressure; Swine; Tumor Cells, Cultured | 2012 |
Chemotherapy-induced toxicity is highly heritable in Drosophila melanogaster.
Topics: Animals; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drosophila melanogaster; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Fertility; Floxuridine; Gemcitabine; High-Throughput Screening Assays; Humans; Methotrexate; Mitomycin; Models, Animal; Neoplasms; Topotecan | 2012 |
Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Cytosine; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Nucleosides | 2012 |
Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lipids; Mice; Nanoparticles; Neoplasms; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2012 |
Incorporation and controlled release of silyl ether prodrugs from PRINT nanoparticles.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Dasatinib; Delayed-Action Preparations; Deoxycytidine; Ethers; Gemcitabine; Humans; Nanoparticles; Neoplasms; Prodrugs; Pyrimidines; Silanes; Thiazoles | 2012 |
High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation.
Topics: Adult; Aged; Asian People; Cytidine Deaminase; Deoxycytidine; Female; Gemcitabine; Gene Frequency; Humans; Male; Middle Aged; Mutation; Neoplasms; Neutropenia; Polymorphism, Genetic | 2012 |
Tumor macrophages as a target for Capsaicin mediated immunotherapy.
Topics: Animals; Antigen Presentation; Antigens, Neoplasm; Apoptosis; Capsaicin; CD11b Antigen; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Forkhead Transcription Factors; Gemcitabine; Immunologic Factors; Immunotherapy; Interleukin-2 Receptor alpha Subunit; Macrophages; Mice; Mice, Inbred BALB C; Neoplasms; Stromal Cells; T-Lymphocytes; T-Lymphocytes, Regulatory; Tumor Microenvironment | 2012 |
[Analysis of risk factors of drug-induced lung injury in patients receiving gemcitabine treatment].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Injury; Male; Middle Aged; Neoplasms; Risk Factors | 2012 |
Synthesis and biological evaluation of oral prodrugs based on the structure of gemcitabine.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biological Availability; Carcinoma, Hepatocellular; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Mice; Neoplasms; Prodrugs | 2012 |
Role of mitochondrial uncoupling protein 2 in cancer cell resistance to gemcitabine.
Topics: Acetylcysteine; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ion Channels; Iridoids; Mitochondrial Proteins; Neoplasms; Poly(ADP-ribose) Polymerases; RNA, Messenger; Superoxide Dismutase; Superoxides; Uncoupling Agents; Uncoupling Protein 2 | 2012 |
Lentivirus-mediated expression of Drosophila melanogaster deoxyribonucleoside kinase driven by the hTERT promoter combined with gemcitabine: a potential strategy for cancer therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Drosophila melanogaster; Female; Gemcitabine; Gene Expression; Gene Order; Genetic Therapy; Genetic Vectors; Humans; Lentivirus; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Prohibitins; Promoter Regions, Genetic; Telomerase | 2012 |
Coadministration of 5% glucose solution relieves vascular pain in the patients administered gemcitabine immediately.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Glucose; Humans; Male; Middle Aged; Neoplasms; Pain; Treatment Outcome | 2013 |
Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Mice; Neoplasms; Ribonucleoside Diphosphate Reductase; RNA Interference; RNA, Small Interfering; Tumor Suppressor Proteins | 2012 |
Novel agents and new combination treatments on phase I studies on solid tumors and pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Neoplasms; Pancreatic Neoplasms; Sirolimus | 2012 |
Hypersensitivity reactions to oxaliplatin: clinical features and risk factors in Koreans.
Topics: Aged; Anaphylaxis; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dexamethasone; Drug Eruptions; Drug Hypersensitivity; Female; Fluorouracil; Gemcitabine; Glucocorticoids; Histamine H1 Antagonists; Humans; Hydrocortisone; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prevalence; Republic of Korea; Retrospective Studies; Risk Factors | 2012 |
Cancer cell-derived supernatants that support the carcinogenic process: a future cancer therapy target?
Topics: Antineoplastic Agents; Cyclophosphamide; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Tumor Microenvironment | 2012 |
Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.
Topics: 5'-Nucleotidase; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Female; Floxuridine; Gemcitabine; Genetic Association Studies; Humans; Male; Metabolic Networks and Pathways; Middle Aged; Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide | 2012 |
Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo.
Topics: Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Arginase; CD11b Antigen; Cell Line, Tumor; Cyclophosphamide; Deoxycytidine; Female; Forkhead Transcription Factors; Gemcitabine; Interferon-gamma; Leukocyte Common Antigens; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred BALB C; Neoplasms; Receptors, Chemokine; T-Lymphocytes; T-Lymphocytes, Regulatory; Tumor Escape | 2013 |
Retrovolution: HIV-driven evolution of cellular genes and improvement of anticancer drug activation.
Topics: Amino Acid Sequence; Animals; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Targeting; Genetic Variation; HIV-1; Humans; Models, Molecular; Molecular Sequence Data; Mutation; Neoplasms; Protein Serine-Threonine Kinases; Sequence Alignment; Vesiculovirus | 2012 |
Site specific/targeted delivery of gemcitabine through anisamide anchored chitosan/poly ethylene glycol nanoparticles: an improved understanding of lung cancer therapeutic intervention.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Benzamides; Cell Line, Tumor; Chitosan; Deoxycytidine; Drug Carriers; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Polyethylene Glycols; Tissue Distribution; Urea | 2012 |
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.
Topics: Animals; Antineoplastic Agents; bcl-2-Associated X Protein; Carrier Proteins; Caspase 1; Cathepsin B; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Dendritic Cells; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Inflammasomes; Interleukin-17; Interleukin-1beta; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neoplasms; NLR Family, Pyrin Domain-Containing 3 Protein; Receptors, Interleukin-1; RNA Interference; RNA, Small Interfering; Signal Transduction | 2013 |
Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses.
Topics: Animals; Cell Communication; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immune Tolerance; Macrophages; Mice; Neoplasm Metastasis; Neoplasms; Neoplastic Stem Cells; Receptor, Macrophage Colony-Stimulating Factor; Receptors, CCR2; STAT3 Transcription Factor; T-Lymphocytes, Cytotoxic | 2013 |
Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Interactions; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Gossypol; Humans; Inhibitory Concentration 50; Multigene Family; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Reproducibility of Results; Signal Transduction; Up-Regulation | 2012 |
H-gemcitabine: a new gemcitabine prodrug for treating cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Binding Sites; Cell Line, Tumor; Deoxycytidine; DNA; Drug Delivery Systems; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasms; Prodrugs | 2013 |
Algorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacy.
Topics: Algorithms; Computer Simulation; Deoxycytidine; Deoxycytidine Kinase; Deoxycytosine Nucleotides; DNA; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Models, Theoretical; Neoplasms; Ribonucleotide Reductases | 2012 |
Dual role of immunomodulation by anticancer chemotherapy.
Topics: Animals; Carrier Proteins; Caspase 1; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Inflammasomes; Neoplasms; NLR Family, Pyrin Domain-Containing 3 Protein | 2013 |
Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Bystander Effect; Carboxylesterase; Deoxycytidine; Deoxyuridine; Female; Gemcitabine; Humans; Hydrolysis; Molecular Structure; Neoplasms; Prodrugs; Recombinant Proteins; RNA, Small Interfering; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
[Hemolytic uremic syndrome induced by gemcitabine. A poorly recognized complication?].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Neoplasms; Renal Dialysis; Renal Insufficiency; Time Factors | 2012 |
Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates.
Topics: Administration, Oral; Alkaline Phosphatase; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cholesterol; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Hydrolysis; Mice; Mice, Nude; Nanostructures; Neoplasms; Particle Size; Permeability; Phosphoric Diester Hydrolases; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy.
Topics: 3T3 Cells; Animals; Carboplatin; Cytokines; Deoxycytidine; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Fibroblast Growth Factor 2; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Neoplasms; Paclitaxel; Transforming Growth Factor beta; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
The radiosensitising effect of gemcitabine and the influence of the rescue agent amifostine in vitro.
Topics: Alkaline Phosphatase; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Gemcitabine; Humans; Lethal Dose 50; Neoplasms; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2003 |
Dose-finding with two agents in Phase I oncology trials.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Biometry; Clinical Trials, Phase I as Topic; Cyclophosphamide; Deoxycytidine; Drug Interactions; Gemcitabine; Humans; Models, Statistical; Neoplasms | 2003 |
Mistletoe and gemcitabine in patients with advanced cancer: a model for the phase I study of botanicals and botanical-drug interactions in cancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Complementary Therapies; Deoxycytidine; Drug Interactions; Gemcitabine; Humans; Models, Theoretical; Neoplasms; Phytotherapy; Plant Extracts; Plant Proteins; Research Design; Viscum album | 2003 |
Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carboplatin; Colonic Neoplasms; Deoxycytidine; Dexamethasone; Drug Synergism; Gemcitabine; Glioma; Half-Life; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasms; Transplantation, Heterologous | 2004 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
Determination of gemcitabine and its metabolite in human plasma using high-pressure liquid chromatography coupled with a diode array detector.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Chromatography, High Pressure Liquid; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Middle Aged; Neoplasms | 2004 |
Fluorescence studies of substrate binding to human recombinant deoxycytidine kinase.
Topics: Adenosine Triphosphate; Antimetabolites, Antineoplastic; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Humans; Kinetics; Ligands; Microscopy, Fluorescence; Neoplasms; Phosphates; Phosphorylation; Protein Binding; Protein Conformation; Recombinant Proteins; Spectrometry, Fluorescence; Substrate Specificity; Uridine Triphosphate | 2004 |
Increased cytotoxicity of 2',2'-difluoro-2'-deoxycytidine in human leukemic cell-lines after a preincubation with cyclopentenyl cytosine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carbon-Nitrogen Ligases; Cell Line, Tumor; Cell Separation; Clinical Trials as Topic; Cytidine; Deoxycytidine; DNA; Dose-Response Relationship, Drug; Flow Cytometry; Gemcitabine; HL-60 Cells; Humans; Necrosis; Neoplasms; Time Factors | 2004 |
Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinosylcytosine (ara-C) in leukemia and solid tumor cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cytarabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatty Acids; Gemcitabine; Humans; Inhibitory Concentration 50; Leukemia; Mice; Neoplasms; Rats; Time Factors | 2004 |
New drugs for cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Serotonin Antagonists | 1998 |
The evolution of cancer research and drug discovery at Lilly Research Laboratories.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Drug Industry; Gemcitabine; Glutamates; Guanine; History, 20th Century; Humans; Indoles; Neoplasms; Pemetrexed; United States | 2005 |
Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria.
Topics: bcl-2-Associated X Protein; bcl-X Protein; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Deoxycytidine; DNA-Binding Proteins; Enzyme Inhibitors; Female; Gemcitabine; Gene Expression; Genes, Tumor Suppressor; Humans; Inhibitory Concentration 50; Leiomyosarcoma; Melanoma; Mitochondria; Morpholines; Neoplasms; Nuclear Proteins; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2005 |
Rob Ashley of AmpliMed discusses the discovery and development of Imexon. Interview by Steve Carney.
Topics: Antineoplastic Agents; Chemistry, Pharmaceutical; Deoxycytidine; Doxycycline; Drug Industry; Drug Synergism; Gemcitabine; Hexanones; Humans; Neoplasms; Tetracyclines | 2005 |
Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Drug Synergism; Female; Fibrosarcoma; Gemcitabine; Lymphoma; Mice; Neoplasm Transplantation; Neoplasms; Paclitaxel; Tumor Necrosis Factor-alpha | 2006 |
Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2006 |
Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1).
Topics: 5' Flanking Region; 5' Untranslated Regions; Amino Acid Substitution; Antimetabolites, Antineoplastic; Asian People; Deoxycytidine; DNA Mutational Analysis; Equilibrative Nucleoside Transporter 1; Exons; Gemcitabine; Genetic Variation; Haplotypes; Humans; Japan; Linkage Disequilibrium; Neoplasms; Polymorphism, Single Nucleotide | 2006 |
[Analysis of antineoplastic drugs used in Cancer Center, Sun Yat-sen University, during the period of 1996-2005].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; China; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Drug Utilization Review; Gemcitabine; Humans; Neoplasms; Paclitaxel; Rituximab; Vinblastine; Vinorelbine | 2006 |
A step in the right direction.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Approval; Endpoint Determination; Female; Gemcitabine; Humans; Neoplasms; Ovarian Neoplasms; Survival Analysis; United States; United States Food and Drug Administration | 2006 |
Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; Female; Gemcitabine; Genotype; Humans; Infusions, Intravenous; Japan; Linkage Disequilibrium; Male; Middle Aged; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Polymorphism, Single Nucleotide | 2007 |
The cumulative incidence of gemcitabine-induced thrombotic microangiopathy.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Iceland; Incidence; Middle Aged; Neoplasms; Peripheral Vascular Diseases; Thrombocytopenia | 2007 |
[MMW drug award for gemcitabine. Cytostatic drug with growing indications].
Topics: Antimetabolites, Antineoplastic; Awards and Prizes; Deoxycytidine; Drug Approval; Gemcitabine; Germany; Neoplasms; Pancreatic Neoplasms; Treatment Outcome | 2006 |
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
Topics: 5'-Nucleotidase; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cytarabine; Cytosine; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Inhibitory Concentration 50; Molecular Structure; Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Taxoids | 2007 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Biomedical Research; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Molecular Structure; Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Piperidines; Prednisolone; Prostatic Neoplasms; Quinazolines; Treatment Outcome | 2007 |
Enhanced efficacy in anti-tumour activity by combined therapy of recombinant FGFR-1 related angiogenesis and low-dose cytotoxic agent.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; Cancer Vaccines; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Immunohistochemistry; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Receptor, Fibroblast Growth Factor, Type 1; Recombinant Proteins | 2007 |
Causes of thrombotic thrombocytopenic purpura.
Topics: Deoxycytidine; Endothelial Cells; Gemcitabine; Humans; Neoplasms; Purpura, Thrombotic Thrombocytopenic | 2007 |
[Gemcitabine and pemetrexed update].
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Neoplasms; Pemetrexed | 2007 |
Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to false-negative results.
Topics: Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; False Negative Reactions; Gemcitabine; Genotype; Humans; Neoplasms; Polymorphism, Genetic; Ribonucleotide Reductases | 2007 |
Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate.
Topics: Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Cross-Over Studies; Deoxycytidine; Drug Interactions; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Models, Biological; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2008 |
Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature.
Topics: Aged; Antimetabolites, Antineoplastic; Brain; Central Nervous System; Deoxycytidine; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Medical Oncology; Neoplasms; Posterior Leukoencephalopathy Syndrome; Risk Factors; Treatment Outcome | 2007 |
Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Gemcitabine; GPI-Linked Proteins; Humans; Membrane Glycoproteins; Mesothelin; Mice; Mice, Nude; Neoplasms; Remission Induction; Xenograft Model Antitumor Assays | 2007 |
Finding clinical meaning in cancer data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Data Interpretation, Statistical; Deoxycytidine; Diarrhea; Erlotinib Hydrochloride; Evidence-Based Medicine; Gemcitabine; Humans; Neoplasms; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sample Size; Survival Analysis | 2007 |
Questions about gemcitabine dose rate: answered or unanswered?
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Neoplasms | 2007 |
Introduction. Gemcitabine: ten years of clinical experience.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasms | 2006 |
Gemcitabine: ten years of clinical experience. Proceedings of a workshop. September 19-21, 2005. Monastier di Treviso, Italy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasms | 2006 |
Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Cytidine Deaminase; Deoxycytidine; Drug Carriers; Drug Stability; Female; Folic Acid; Gemcitabine; HeLa Cells; Humans; Mice; Mice, Inbred BALB C; Neoplasms; Polyethylene Glycols; Prodrugs | 2008 |
Kinetic investigation of the inhibitory effect of gemcitabine on DNA polymerization catalyzed by human mitochondrial DNA polymerase.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; DNA Polymerase gamma; DNA Replication; DNA-Directed DNA Polymerase; DNA, Mitochondrial; Gemcitabine; Humans; Kinetics; Mitochondrial Diseases; Neoplasms | 2008 |
Gemcitabine--status of preclinical studies and perspectives for future clinical applications of this novel nucleoside analog. Symposium proceedings. Amsterdam, The Netherlands, March 15, 1994.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; DNA, Neoplasm; Drug Interactions; Drug Resistance, Neoplasm; Gemcitabine; Humans; Neoplasms; Ribonucleotide Reductases; RNA, Neoplasm; Tumor Cells, Cultured | 1995 |
Gemcitabine: novel combination of efficacy and tolerability.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasms | 1993 |
Regulation of deoxycytidine kinase activity and inhibition by DFDC.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Cycloheximide; Dactinomycin; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Humans; Neoplasms; Pyrimidine Nucleotides; Rats; Tumor Cells, Cultured | 1993 |
The influence of BIBW22BS, a dipyridamole derivative, on the antiproliferative effects of 5-fluorouracil, methotrexate and gemcitabine in vitro and in human tumour xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Deoxycytidine; Dipyridamole; Doxorubicin; Drug Resistance; Female; Floxuridine; Fluorouracil; Gemcitabine; Humans; Methotrexate; Mice; Mice, Nude; Morpholines; Neoplasms; Neoplasms, Experimental; Protein Binding; Transplantation, Heterologous; Triamterene; Tumor Cells, Cultured; Vincristine | 1995 |
Gemcitabine hydrochloride: combination of activity and tolerability. Proceedings of a symposium. Jerusalem, Israel, November 14, 1993.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasms | 1995 |
Clinical trials referral resource. Clinical trials using gemcitabine.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cytidine Deaminase; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Neoplasms; Nucleic Acid Synthesis Inhibitors; Nucleoside Deaminases | 1996 |
Gemcitabine: a case study for clinical benefit.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Neoplasms | 1996 |
Gemcitabine: we've reached the end of the beginning.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Neoplasms | 1996 |
Weekly short infusions of gemcitabine are not associated with suppression of lymphatic activity in patients with solid tumors.
Topics: Antimetabolites, Antineoplastic; CD4-CD8 Ratio; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Killer Cells, Natural; Lymphocytes; Male; Neoplasms | 1997 |
High susceptibility of human cancer xenografts with higher levels of cytidine deaminase to a 2'-deoxycytidine antimetabolite, 2'-deoxy-2'-methylidenecytidine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cytidine Deaminase; Deoxycytidine; Disease Susceptibility; Enzyme Inhibitors; Female; Gemcitabine; Humans; Kinetics; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 1998 |
There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Eflornithine; Gemcitabine; Humans; Mitoguazone; Neoplasms; Research Design | 1998 |
Cancer treatment in Sweden--costs of drugs, inpatient and outpatient care from 1985 to 1996 and cost effectiveness of new drugs.
Topics: Ambulatory Care; Androgen Antagonists; Antineoplastic Agents; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Filgrastim; Gemcitabine; Gonadotropin-Releasing Hormone; Granulocyte Colony-Stimulating Factor; Humans; Neoplasms; Paclitaxel; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Recombinant Proteins; Sweden | 1998 |
Gemcitabine--a major advance?
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; DNA Replication; DNA, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasms; Pancreatic Neoplasms | 1998 |
Severe non-haematological toxicity after treatment with gemcitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Lung Diseases; Male; Middle Aged; Neoplasms; Retrospective Studies; Tomography, X-Ray Computed; Ventricular Dysfunction | 1999 |
Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters.
Topics: Animals; Antimetabolites, Antineoplastic; Biological Transport; Carrier Proteins; Cell Membrane; Deoxycytidine; Electrophysiology; Gemcitabine; Membrane Proteins; Neoplasms; Nucleosides; Oocytes; Recombinant Proteins; Sodium Channels; Uridine; Xenopus laevis | 1999 |
Time- and dose-limiting erysipeloid rash confined to areas of lymphedema following treatment with gemcitabine--a report of three cases.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Eruptions; Erysipeloid; Exanthema; Female; Gemcitabine; Humans; Lymphedema; Middle Aged; Neoplasms | 2000 |
Quality of life and cisplatin-gemcitabine chemotherapy.
Topics: Antineoplastic Agents; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Quality of Life | 2000 |
The clinical implications of gemcitabine radiosensitization.
Topics: Apoptosis; Caspases; Cell Survival; Cobalt Radioisotopes; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Radiation-Sensitizing Agents | 2001 |
Evaluating new treatments for advanced cancer.
Topics: Antineoplastic Agents; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Bystander effects of nucleoside analogs phosphorylated in the cytosol or mitochondria.
Topics: Animals; CHO Cells; Cricetinae; Cytarabine; Cytosol; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Genetic Therapy; Mitochondria; Neoplasms; Nucleosides; Phosphorylation | 2001 |
Increased deoxycytidine kinase activity in cancer cells and inhibition by difluorodeoxycytidine.
Topics: Animals; Cell Division; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Humans; In Vitro Techniques; Kinetics; Neoplasms; Rats; Tumor Cells, Cultured | 1992 |